
<html lang="en"     class="pb-page"  data-request-id="7f710c24-c20d-45ca-a8db-0988c9ed5792"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.5b01136;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation" /></meta><meta name="dc.Creator" content="John M.  Hatcher" /></meta><meta name="dc.Creator" content="Magda  Bahcall" /></meta><meta name="dc.Creator" content="Hwan Geun  Choi" /></meta><meta name="dc.Creator" content="Yang  Gao" /></meta><meta name="dc.Creator" content="Taebo  Sim" /></meta><meta name="dc.Creator" content="Rani  George" /></meta><meta name="dc.Creator" content="Pasi A.  Jänne" /></meta><meta name="dc.Creator" content="Nathanael S.  Gray" /></meta><meta name="dc.Description" content="The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib,..." /></meta><meta name="Description" content="The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib,..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 25, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01136" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01136" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01136" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01136" /></link>
        
    
    

<title>Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01136" /></meta><meta property="og:title" content="Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0015.jpeg" /></meta><meta property="og:description" content="The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS). This has motivated the development of “second-generation” ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance. However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations. Herein, we report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R mutant as well as a variety of other frequently observed mutants. In addition, JH-VIII-157-02 is capable of penetrating the CNS of mice following oral dosing." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01136"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01136">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01136&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01136&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01136&amp;href=/doi/10.1021/acs.jmedchem.5b01136" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9296-9308</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01088" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01312" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Hatcher">John M. Hatcher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Magda++Bahcall">Magda Bahcall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hwan+Geun++Choi">Hwan Geun Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Gao">Yang Gao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taebo++Sim">Taebo Sim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rani++George">Rani George</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pasi+A.++J%C3%A4nne">Pasi A. Jänne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathanael+S.++Gray">Nathanael S. Gray</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Cancer Biology, <sup>‡</sup>Lowe Center for Thoracic Oncology, and <sup>§</sup>Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">⊥</span> <span class="aff-text">Department of Pediatric Haematology and Oncology, Dana-Farber Cancer Institute and Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02215, United States</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">#</span> <span class="aff-text">Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul 136-791, Korea</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">∇</span> <span class="aff-text">KU-KIST Graduate School of Converging Science and Technology, 145 Anam-ro, Seongbuk-gu, Seoul 136-713, Korea</span></div><div class="corresp-info"><strong>*</strong>E-mail <a href="/cdn-cgi/l/email-protection#86c8e7f2eee7e8e7e3ead9c1f4e7ffc6e2e0e5efa8eee7f4f0e7f4e2a8e3e2f3"><span class="__cf_email__" data-cfemail="8ac4ebfee2ebe4ebefe6d5cdf8ebf3caeeece9e3a4e2ebf8fcebf8eea4efeeff">[email protected]</span></a>. Phone: 617-582-8590.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01136&amp;href=/doi/10.1021%2Facs.jmedchem.5b01136" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9296–9308</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 14, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 August 2015</li><li><span class="item_label"><b>Published</b> online</span>25 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01136" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01136</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9296%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn%2BM.%2BHatcher%252C%2BMagda%2BBahcall%252C%2BHwan%2BGeun%2BChoi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D23%26contentID%3Dacs.jmedchem.5b01136%26title%3DDiscovery%2Bof%2BInhibitors%2BThat%2BOvercome%2Bthe%2BG1202R%2BAnaplastic%2BLymphoma%2BKinase%2BResistance%2BMutation%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9308%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01136"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3459</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01136" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Hatcher&quot;},{&quot;first_name&quot;:&quot;Magda&quot;,&quot;last_name&quot;:&quot;Bahcall&quot;},{&quot;first_name&quot;:&quot;Hwan&quot;,&quot;last_name&quot;:&quot;Geun Choi&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Taebo&quot;,&quot;last_name&quot;:&quot;Sim&quot;},{&quot;first_name&quot;:&quot;Rani&quot;,&quot;last_name&quot;:&quot;George&quot;},{&quot;first_name&quot;:&quot;Pasi&quot;,&quot;last_name&quot;:&quot;A. Jänne&quot;},{&quot;first_name&quot;:&quot;Nathanael&quot;,&quot;last_name&quot;:&quot;S. Gray&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9296-9308&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01136&quot;},&quot;abstract&quot;:&quot;The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS). This has motivated the development of “second-generation” ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance. However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations. Herein, we report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R mutant as well as a variety of other frequently observed mutants. In addition, JH-VIII-157-02 is capable of penetrating the CNS of mice following oral dosing.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01136&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01136" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01136&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01136" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01136&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01136" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01136&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01136&amp;href=/doi/10.1021/acs.jmedchem.5b01136" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01136" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01136" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01136%26sid%3Dliteratum%253Aachs%26pmid%3D26568289%26genre%3Darticle%26aulast%3DHatcher%26date%3D2015%26atitle%3DDiscovery%2Bof%2BInhibitors%2BThat%2BOvercome%2Bthe%2BG1202R%2BAnaplastic%2BLymphoma%2BKinase%2BResistance%2BMutation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D23%26spage%3D9296%26epage%3D9308%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/jmcmar.2015.58.issue-23/20151210/jmcmar.2015.58.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS). This has motivated the development of “second-generation” ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance. However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations. Herein, we report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R mutant as well as a variety of other frequently observed mutants. In addition, JH-VIII-157-02 is capable of penetrating the CNS of mice following oral dosing.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div id="ac_i1" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i1"> </h2><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. Expression of ALK in normal human tissue is limited to a subset of neural cell types.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> No essential role for ALK has been found in mammals. ALK knockout mice live a full life span without any obvious abnormalities, but display a resistance to depressive phenotypes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, aberrent expression and hyperactivation of ALK due to translocations or point mutations have been shown to be oncogenic in a large variety of cancers.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Deregulation of ALK was first identified in anaplastic large-cell lymphoma (ALCL), a subtype of non-Hodgkins lymphoma, in which the t(2;5)(p32;q35) chromosomal translocation involving the ALK gene was first described.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This translocation results in the fusion of nucleophosmin (NPM) to a truncated form of ALK, which results in a constitutive activation of the kinase domain, leading to an “oncogene-addicted” state in several tumor types, including inflammatory myofibroblastic tumors (IMTs),<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> diffuse large B-cell lymphoma (DLBCL),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> squamous cell carcinoma,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and non-small-cell lung carcinoma (NSCLC).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Germline mutations in ALK are the cause of the majority of hereditary neuroblastoma cases, and ALK activating mutations and/or gene amplifications are functionally relevant in high-risk sporadic neuroblastoma.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Lung cancers with ALK rearrangements are highly sensitive to ALK tyrosine kinase inhibition, further underscoring the notion that such cancers are addicted to ALK kinase activity. The multitargeted kinase inhibitor crizotinib was approved by the FDA in 2011 to treat patients with advanced NSCLC harboring ALK rearrangements.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, despite a high response rate of 60% in ALK rearranged NSCLC, most patients develop resistance to crizotinib after 1 year of treatment.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> In particular, the central nervous system (CNS) is one of the most common sites of relapse in patients with ALK-positive NSCLC.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Studies of lung cancers harboring ALK rearrangements with acquired resistance to crizotinib have identified ALK fusion gene amplification and secondary ALK kinase domain mutations in approximately one-third of cases.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> The most frequently identified secondary mutations are L1196 M (gatekeeper mutation), G1269A, 1151T-ins, L1152R, C1156Y, G1202R, F1174L, and S1206Y.<a onclick="showRef(event, 'ref16 ref19 ref20 ref21 ref22 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref16 ref19 ref20 ref21 ref22 ref21 ref22">(16, 19-22, 21, 22)</a> While L1196 M is the most frequently identified secondary mutation in crizotinib-resistant patients (22–36%),<a onclick="showRef(event, 'ref16 ref18 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref18 ref23">(16, 18, 23)</a> the distribution changes dramatically in ceritinib- and alectinib-treated patients. Ceritinib is significantly more potent against the majority of crizotinib-resistant mutants but is ineffective against G1202R and F1174C/V. Hence, those two mutants tend to be the only ones identified in ceritinib-resistant patients. In one study, 20% of ceritinib-resistant patients harbored the G1202R mutation only, 10% harbored the F1174C/V mutation only, 10% of patients harbored both G1202R and F1174C mutations, and 60% presented with a wild-type ALK kinase domain.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Hence, in this study G1202R is the leading ALK secondary mutation causing resistance to ceritinib, accounting for 75% of all identified ALK secondary mutations in ceritinib-resistant patients. As alectinib-resistant patients slowly emerge, a profile similar to that of ceritinib resistance has been reported, identifying the G1202R and F1174V mutations in patients.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Several second-generation ALK inhibitors have been developed in an attempt to overcome resistance due to these secondary mutants; however, the G1202R mutant confers resistance to all clinical stage ALK inhibitors<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Herein, we report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R mutant as well as the most common reported mutants (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cell-Based Phospho-ALK IC<sub>50</sub> Data of Common Secondary ALK Mutations for Clinical ALK Inhibitors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">EA wt</th><th class="colsep0 rowsep0" align="center" char=".">EA C1156Y</th><th class="colsep0 rowsep0" align="center" char=".">EA F1174L</th><th class="colsep0 rowsep0" align="center" char=".">EA L1196M</th><th class="colsep0 rowsep0" align="center" char=".">EA L1152R</th><th class="colsep0 rowsep0" align="center" char=".">EA 1151Tins</th><th class="colsep0 rowsep0" align="center" char=".">EA G1202R</th><th class="colsep0 rowsep0" align="center" char=".">EA G1269A</th><th class="colsep0 rowsep0" align="center" char=".">EA S1206Y</th><th class="colsep0 rowsep0" align="center">untransduced Ba/F3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b>, AF802 (alectinib)</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">169</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left"> >10<sup>3</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b>, LDK378 (ceritinib)</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">164</td><td class="colsep0 rowsep0" align="char" char=".">101</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">2747</td><td class="colsep0 rowsep0" align="char" char=".">668</td><td class="colsep0 rowsep0" align="char" char=".">444</td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="left">5512</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b>, AP26113 (brigatinib)</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">2300</td><td class="colsep0 rowsep0" align="char" char=".">142</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">1921</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>, crizotinib (Xalkori)</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">144</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">549</td><td class="colsep0 rowsep0" align="char" char=".">645</td><td class="colsep0 rowsep0" align="char" char=".">857</td><td class="colsep0 rowsep0" align="char" char=".">328</td><td class="colsep0 rowsep0" align="char" char=".">512</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="left">927</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b>, PF-06463922<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b>, JH-VIII-157-02</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">196</td><td class="colsep0 rowsep0" align="char" char=".">107</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">591</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">EA = EML4-ALK. EML4-ALK<sup>WT</sup> or secondary mutant transformed Ba/F3 cells or the untransduced Ba/F3 control was treated with ALK inhibitors in a dose escalation MTS assay and assessed for viability after 72 h. Untransduced Ba/F3 cells served as a cytotoxicity control. Average IC<sub>50</sub> values (<i>n</i> = 3) are shown.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Published data.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></p></div></div></div><div class="NLM_p">We chose to target the ALK G1202R mutant using the alectinib scaffold based on the cocrystal structure of alectinib and EML4-ALK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A). We conducted a molecular modeling study incorporating the 1202R mutation and found that the morpholinopiperidine ring of alectinib is predicted to be in very close proximity to the G1202 residue, and therefore is likely responsible for the loss of activity in the G1202R mutant due to steric clash with the 1202R residue (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). We imagined replacing the bulky morpholinopiperidine ring with smaller substituents would avoid this steric clash and result in a potent inhibitor of the G1202R mutant. This coupled with the commercial availability of the tetracyclic core <b>37</b> provided a convenient entry point to the development of a potent inhibitor of the ALK G1202R mutant.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of <b>1</b> in complex with wild-type ALK and docked pose of <b>1</b> with a molecular model of ALK<sup>G1202R</sup>. (A) Binding conformation of <b>1</b> (yellow stick) in the ATP binding site of ALK<sup>WT</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>). Hydrogen bonds are indicated by dashed lines. (B) Binding conformation of <b>1</b> in the ATP binding site of ALK with a model of the G1202R mutation. Hydrogen bonds are indicated by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To assess the potency of our newly synthesized compounds, we tested them against Ba/F3 cells in a single-point inhibition assay at a concentration of 1 μM (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compounds that showed potent inhibition of the G1202R mutant without showing potent inhibition of untransduced Ba/F3 cells in the single-point inhibition assay were then taken forward and tested against a panel of the most common secondary ALK mutants to determine cellular phospho-ALK IC<sub>50</sub> values (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Single-Point Inhibition Assay of Alectinib Analogues against EML4-ALK<sup>WT</sup>, EML4-ALK<sup>G1202R</sup>, and Untransduced Ba/F3 Cells<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0012.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">EA = EML4-ALK. EML4-ALK<sup>WT</sup> or EML4-ALK<sup>G1202R</sup> transformed Ba/F3 cells or the untransduced Ba/F3 control was treated with a single dose (1 μM) of alectinib analogues. The percent viability of the untreated control for each compound was determined by MTS assay after 72 h.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values of Select Alectinib Analogues against a Panel of the Most Common Secondary EML4-ALK Mutants<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0013.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0014.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">EA = EML4-ALK. EML4-ALK<sup>WT</sup> or secondary mutant transformed Ba/F3 cells or the untransduced Ba/F3 control was treated with selected alectinib analogues in a dose escalation MTS assay and assessed for viability after 72 h. Untransduced Ba/F3 cells served as a cytotoxicity control.</p></div></div><div></div></div><div class="NLM_p">We began by replacing the morpholinopiperidine ring with small aromatic heterocycles, including pyrazoles (<b>8</b> and <b>9</b>), methylpyrazole (<b>7</b>), isoxazole (<b>10</b>), furan (<b>11</b>), thiophene (<b>12</b>), triazole (<b>13</b>), pyridines (<b>14</b> and <b>15</b>), and pyrimidine (<b>16</b>). We hypothesized that these compounds might be active because they were smaller and possess a basic nitrogen capable of forming a hydrogen bond with the guanidine moiety of the 1202R. Compounds <b>7</b>, <b>8</b>, and <b>9</b> were quite potent against the G1202R mutant in a single-point inhibition assay at a concentration of 1 μM. Compounds lacking a basic nitrogen (<b>11</b> and <b>12</b>) showed much less inhibitory activity. Compounds <b>7</b>, <b>8</b>, and <b>9</b> were then tested against a panel of the most common secondary ALK mutants to obtain IC<sub>50</sub> values, where we found that these compounds were indeed potent against the G1202R mutant with IC<sub>50</sub> values ranging from 21 to 32 nM. However, they lost activity against all of the other mutants compared to alectinib. We then synthesized smaller alkyl ring versions of the morpholinopiperidine tail of alectinib, including (dimethylamino)piperidine (<b>17</b>), piperazine (<b>18</b>), methylpiperazine (<b>19</b>), and morpholine (<b>20</b>). We thought that by shortening the morpholinopiperidine ring we might be able to avoid the steric clash caused by the 1202R mutation while maintaining potency against the other common ALK mutants. Additionally, we introduced diols (<b>22</b> and <b>23</b>), a carboxylic acid (<b>24</b>), a cyano group (<b>21</b>), and the open-ring version of methylpiperazine (<b>29</b>) since they are even smaller than the pyrazoles and are potentially capable of forming hydrogen bonds with the guanidine moiety of the 1202R; however, these compounds were much less potent against the G1202R mutant in the single-point inhibition assay. The diminished activity is likely due to a loss of structural rigidity compared to the aromatic heterocycles. The allylmorpholine derivative (<b>25</b>) was prepared with the rationale that the double bond would avoid steric clash with 1202R, while still possessing a solubilizing group; however, this compound showed no activity in the single-point inhibition assay. Compounds <b>17</b> and <b>19</b> showed potent inhibition at 1 μM; however, when IC<sub>50</sub> values were calculated for these compounds, we observed a loss of potency against the G1202R mutant and an increase in potency against the other secondary mutants. This suggested that an aromatic ring was necessary to avoid steric clash with the 1202R. We then decided to make substituted pyridines (<b>26</b> and <b>27</b>) and substituted pyrazoles (<b>6</b>, <b>29</b>–<b>33</b>, <b>35</b>, and <b>36</b>) to avoid the steric clash from 1202R and introduce a group capable of forming additional hydrogen bonds to increase potency. The substituted pyrazoles (<b>6</b>, <b>29</b>–<b>33</b>, <b>35</b>, and <b>36</b>) were quite potent against the G1202R mutant at 1 μM. Interestingly, compound <b>33</b> showed potent activity against untransduced Ba/F3 cells, and therefore, IC<sub>50</sub> values were not calculated for this compound. Compound <b>6</b> was extremely potent against the G1202R mutant with an IC<sub>50</sub> of 2 nM, which is a 100-fold increase in cellular potency compared to that of alectinib. The activity of compound <b>6</b> was further tested in Ba/F3 cells transformed with CD74-ROS or EGFR exon 19 deletion as specificity controls, untransduced Ba/F3 cells as the cytotoxicity control, and other common EML4-ALK crizotinib-resistant secondary mutants, many of which are unavailable in primary cell lines (see Figure 2 and Table 1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf" class="ext-link">Supporting Information</a>). In addition to potently inhibiting the G1202R mutant, compound <b>6</b> exhibited improved potency against the L1152R mutant in Ba/F3 cells. The potency and on-target inhibition of phospho-EML4-ALK by compound <b>6</b> was further confirmed by Western blotting in NIH-3t3 cells transformed with wild-type EML4-ALK or its crizotinib-resistant secondary mutants (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), showing in particular the potent inhibitory activity against the G1202R mutant.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Western blotting in NIH-3t3 cells transformed with wild-type EML4-ALK or its crizotinib-resistant secondary mutants. (A) Western blotting of crizotinib, ceritinib, alectinib, and compound <b>6</b> against EML4-ALK<sup>WT</sup> NIH-3T3 and EML4-ALK<sup>G1202R</sup> NIH-3T3. (B) Western blotting of crizotinib, ceritinib, alectinib, and compound <b>6</b> against crizotinib-resistant mutants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To better understand the structure–activity relationships, we performed a molecular modeling study based upon the cocrystal structure of ALK with alectinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This study suggested that compound <b>6</b> makes the same backbone hinge contact as alectinib; however, compound <b>6</b> forms two additional hydrogen bond interactions between the guanidine moiety of R1120 and the carbonyl group of the dimethylacetamide group (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Furthermore, in the G1202R mutant, compound <b>6</b> forms an additional hydrogen bond interaction between the guanidine moiety of R1202 and the nitrogen of the pyrazole ring (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). The modeling study predicted that the methylene spacer between the pyrazole ring and the dimethylacetamide moiety is required for the carbonyl amide of <b>6</b> to interact with the guanidine moiety of R1120.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Molecular docking study of <b>6</b> with wild-type ALK and a model of G1202R ALK. (A) Binding conformation of <b>6</b> (yellow sticks) in the ATP binding site of ALK<sup>WT</sup> (blue ribbon). Hydrogen bonds are indicated by dashed lines. (B) Predicted binding conformation of <b>6</b> (yellow sticks) in the ATP binding site of ALK<sup>G1202R</sup>. Hydrogen bonds are indicated by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate the inhibitory activity of these new ALK kinase inhibitors against different ALK fusion and mutant ALK kinases, the most potent compounds (<b>6</b>, <b>31</b>, and <b>32</b>) as well as the clinical stage ALK inhibitors alectinib, ceritinib (LDK378), AP26113 (brigatinib), and crizotinib (Xalkori) were tested against a panel of cell lines derived from NSCLC (H3122, DFCI76, and DFCI114) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>; see also Table 1 and Figure 2 in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf" class="ext-link">Supporting Information</a>) and neuroblastoma (Kelly, LAN-1, SH-SY5Y (F1174L), SK-N-SH (F1174L), LAN-5 (R1275Q), SMS-KCNR (R1275Q), CHLA-20 (R1275Q), SK-N-BE2 (wt), SK-N-FI (wt), and SK-N-AS (wt)) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) (see also Figure 3 in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf" class="ext-link">Supporting Information</a>). These selected cell lines showed varied patterns of sensitivity to the growth inhibitory activity of <b>6</b>, <b>31</b>, and <b>32</b>. This likely reflects a combination of the degree to which the antiproliferative activity is “on-target” to ALK versus other targets of these compounds and the degree to which each of these cell lines is dependent upon ALK kinase activity. Compounds <b>6</b> and <b>32</b> possessed submicromolar EC<sub>50</sub> values across the entire panel of cell lines. Compound <b>6</b> showed a marked increase in potency against all of the neuroblastoma cell lines and the ALK TKI-sensitive H3122 cells, and was comparable to alectinib against the L1152R EML4-ALK mutant DFCI76 cell line. The L1152R EML4-ALK mutant Ba/F3 cells were more potently inhibited by compound <b>6</b> than alectinib (see Table 1 and Figure 1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf" class="ext-link">Supporting Information</a>) possibly due to the fact that in DFCI76 the EML4-ALK activity of compound <b>6</b> was masked by the activation of EGFR signaling, an additional known resistance mechanism in DFCI76. The mutant EGFR PC9 cell line was not inhibited by compound <b>6</b>, further demonstrating the on-target effect of this compound. Interestingly, compound <b>32</b> was more potent in the neuroblastoma cell lines than compound <b>6</b>. Further testing is under way to understand the difference in potencies between the two compounds.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative EC<sub>50</sub> Values of Compounds Tested against a Panel of NSCLC and Neuroblastoma Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char=".">EC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">MYCN</th><th class="colsep0 rowsep0" align="center">histology</th><th class="colsep0 rowsep0" align="center" char="."><b>31</b></th><th class="colsep0 rowsep0" align="center" char="."><b>32</b></th><th class="colsep0 rowsep0" align="center" char="."><b>6</b></th><th class="colsep0 rowsep0" align="center" char="."><b>1</b>, alectinib</th><th class="colsep0 rowsep0" align="center" char="."><b>2</b>, LDK378</th><th class="colsep0 rowsep0" align="center" char="."><b>3</b>, AP26113</th><th class="colsep0 rowsep0" align="center" char="."><b>4</b>, crizotinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H3122</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DFCI76 (L1152R)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">511</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">233</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DFCI114 (G1269A)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="char" char=".">535</td><td class="colsep0 rowsep0" align="char" char=".">863</td><td class="colsep0 rowsep0" align="char" char=".">419</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">1615</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Kelly (F1174L)</td><td class="colsep0 rowsep0" align="left">amplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">164</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">147</td><td class="colsep0 rowsep0" align="char" char=".">434</td><td class="colsep0 rowsep0" align="char" char=".">142</td><td class="colsep0 rowsep0" align="char" char=".">127</td><td class="colsep0 rowsep0" align="char" char=".">211</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LAN-1 (F1174L)</td><td class="colsep0 rowsep0" align="left">amplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">494</td><td class="colsep0 rowsep0" align="char" char=".">265</td><td class="colsep0 rowsep0" align="char" char=".">571</td><td class="colsep0 rowsep0" align="char" char=".">2004</td><td class="colsep0 rowsep0" align="char" char=".">549</td><td class="colsep0 rowsep0" align="char" char=".">2853</td><td class="colsep0 rowsep0" align="char" char=".">1346</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SH-SY5Y (F1174L)</td><td class="colsep0 rowsep0" align="left">nonamplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">451</td><td class="colsep0 rowsep0" align="char" char=".">264</td><td class="colsep0 rowsep0" align="char" char=".">413</td><td class="colsep0 rowsep0" align="char" char=".">1150</td><td class="colsep0 rowsep0" align="char" char=".">186</td><td class="colsep0 rowsep0" align="char" char=".">986</td><td class="colsep0 rowsep0" align="char" char=".">523</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-N-SH (F1174L)</td><td class="colsep0 rowsep0" align="left">nonamplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">252</td><td class="colsep0 rowsep0" align="char" char=".">161</td><td class="colsep0 rowsep0" align="char" char=".">245</td><td class="colsep0 rowsep0" align="char" char=".">872</td><td class="colsep0 rowsep0" align="char" char=".">303</td><td class="colsep0 rowsep0" align="char" char=".">1988</td><td class="colsep0 rowsep0" align="char" char=".">370</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LAN-5 (R1275Q)</td><td class="colsep0 rowsep0" align="left">amplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">152</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">192</td><td class="colsep0 rowsep0" align="char" char=".">617</td><td class="colsep0 rowsep0" align="char" char=".">122</td><td class="colsep0 rowsep0" align="char" char=".">790</td><td class="colsep0 rowsep0" align="char" char=".">232</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMS-KCNR (R1275Q)</td><td class="colsep0 rowsep0" align="left">amplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">129</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">133</td><td class="colsep0 rowsep0" align="char" char=".">765</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">535</td><td class="colsep0 rowsep0" align="char" char=".">179</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHLA-20 (R1275Q)</td><td class="colsep0 rowsep0" align="left">nonamplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">119</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">218</td><td class="colsep0 rowsep0" align="char" char=".">430</td><td class="colsep0 rowsep0" align="char" char=".">363</td><td class="colsep0 rowsep0" align="char" char=".">8667</td><td class="colsep0 rowsep0" align="char" char=".">439</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-N-BE2 (wt)</td><td class="colsep0 rowsep0" align="left">amplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">1149</td><td class="colsep0 rowsep0" align="char" char=".">752</td><td class="colsep0 rowsep0" align="char" char=".">623</td><td class="colsep0 rowsep0" align="char" char=".">1554</td><td class="colsep0 rowsep0" align="char" char=".">593</td><td class="colsep0 rowsep0" align="char" char=".">2928</td><td class="colsep0 rowsep0" align="char" char=".">710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-N-FI (wt)</td><td class="colsep0 rowsep0" align="left">nonamplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">914</td><td class="colsep0 rowsep0" align="char" char=".">567</td><td class="colsep0 rowsep0" align="char" char=".">973</td><td class="colsep0 rowsep0" align="char" char=".">2401</td><td class="colsep0 rowsep0" align="char" char=".">349</td><td class="colsep0 rowsep0" align="char" char=".">2645</td><td class="colsep0 rowsep0" align="char" char=".">1469</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-N-AS (wt)</td><td class="colsep0 rowsep0" align="left">nonamplified</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="char" char=".">871</td><td class="colsep0 rowsep0" align="char" char=".">465</td><td class="colsep0 rowsep0" align="char" char=".">775</td><td class="colsep0 rowsep0" align="char" char=".">2139</td><td class="colsep0 rowsep0" align="char" char=".">1045</td><td class="colsep0 rowsep0" align="char" char=".">776</td><td class="colsep0 rowsep0" align="char" char=".">1473</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Cells were seeded at 4000 per well in 96-well plates and exposed to each compound in triplicate at 1 nM to 10 μM for 72 h. Cell viability was evaluated using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) following the manufacturer’s instruction. IC<sub>50</sub> values were calculated by nonlinear regression (variable slope) using GraphPad Prism 5 software. Each experiment was repeated at least two times.</p></div></div></div><div class="NLM_p">With the potent antiproliferative activities of these new ALK inhibitors established, we assessed the selectivity of this scaffold using the KINOME<i>scan</i> methodology across a panel of 456 kinases (Ambit Biosciences, San Diego, CA).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Compounds <b>6</b> and <b>32</b> were screened at a concentration of 1 μM (see the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf" class="ext-link">Supporting Information</a> for complete profiling data). Both compounds were slightly less selective than the parent compound alectinib. Compound <b>6</b> was more selective than compound <b>32</b> with 34 interactions mapped compared to 39 with an S-score(1) = 0.06, which may explain the increase in cytotoxicity against the neuroblastoma cell lines (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Dose–response analysis using compound <b>6</b> revealed inhibition of CSNK2A1 with an IC<sub>50</sub> < 10 μM, IRAK1 with an IC<sub>50</sub> = 14 nM, IRAK 4 with an IC<sub>50</sub> = 465 nM, CLK4 with an IC<sub>50</sub> = 14 nM, RET with an IC<sub>50</sub> = 3 nM, RET V804L with an IC<sub>50</sub> = 13 nM, and RET V804 M with an IC<sub>50</sub> = 12 nM. Dose–response analysis using compound <b>32</b> revealed inhibition of CSNK2A1 with an IC<sub>50</sub> < 10 μM, IRAK1 with an IC<sub>50</sub> = 15 nM, IRAK 4 with an IC<sub>50</sub> = 234 nM, CLK4 with an IC<sub>50</sub> = 4 nM, RET with an IC<sub>50</sub> = 2 nM, RET V804L with an IC50 = 9 nM, and RET V804 M with an IC<sub>50</sub> = 23 nM.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ambit kinomescan selectivity results for compounds <b>6</b> and <b>32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The mouse pharmacokinetic profile of <b>6</b> demonstrated good oral bioavailability (<i>F</i> = 87%), a half-life of 1.69 h, and a plasma exposure of 64 635 (min ng)/mL (AUC<sub>last</sub>) following an oral dose of 10 mg/kg (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Additionally, 2 h after an oral dose of 10 mg/kg, <b>6</b> showed a plasma exposure of 0.34 μM and a brain exposure of 0.03 μM (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>), which equate to a low total brain/plasma concentration ratio of 0.1. Because compound <b>32</b> was more potent in neuroblastoma cell lines, we decided to evaluate its pharmacokinetic properties. Compound <b>32</b> showed lower oral bioavailability (<i>F</i> = 26%), a half-life of 4.7 h, and a plasma exposure of 109 909 (min ng)/mL (AUClast) following an oral dose of 10 mg/kg (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Additionally, 2 h after an oral dose of 10 mg/kg, <b>32</b> showed a plasma exposure of 0.21 μM and a brain exposure of 0.03 μM (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>), which equate to a low total brain/plasma concentration ratio of 0.14.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Properties of Compounds <b>6</b> and <b>32</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">matrix</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>l/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> [(min ng)/mL]</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (μM h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC <sub>INF,obsd</sub> [(min ng)/mL]</th><th class="colsep0 rowsep0" align="center" char=".">AUC (%extrap)</th><th class="colsep0 rowsep0" align="center" char=".">CI<sub>obsd</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss,obsd</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1.64</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">35250</td><td class="colsep0 rowsep0" align="char" char=".">75.71</td><td class="colsep0 rowsep0" align="char" char=".">150478</td><td class="colsep0 rowsep0" align="char" char=".">27.56</td><td class="colsep0 rowsep0" align="char" char=".">780621</td><td class="colsep0 rowsep0" align="char" char=".">1.74</td><td class="colsep0 rowsep0" align="char" char=".">3.55</td><td class="colsep0 rowsep0" align="char" char=".">0.38</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.69</td><td class="colsep0 rowsep0" align="char" char=".">0.83</td><td class="colsep0 rowsep0" align="char" char=".">373</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">655320</td><td class="colsep0 rowsep0" align="char" char=".">2.31</td><td class="colsep0 rowsep0" align="char" char=".">67036</td><td class="colsep0 rowsep0" align="char" char=".">3.66</td><td class="colsep0 rowsep0" align="char" char=".">154.83</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>32</b></td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3.06</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">1005</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td><td class="colsep0 rowsep0" align="char" char=".">85807</td><td class="colsep0 rowsep0" align="char" char=".">3.07</td><td class="colsep0 rowsep0" align="char" char=".">96619</td><td class="colsep0 rowsep0" align="char" char=".">12.68</td><td class="colsep0 rowsep0" align="char" char=".">23.27</td><td class="colsep0 rowsep0" align="char" char=".">4.98</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">4.79</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char=".">640</td><td class="colsep0 rowsep0" align="char" char=".">1.38</td><td class="colsep0 rowsep0" align="char" char=".">109909</td><td class="colsep0 rowsep0" align="char" char=".">3.94</td><td class="colsep0 rowsep0" align="char" char=".">154859</td><td class="colsep0 rowsep0" align="char" char=".">29.71</td><td class="colsep0 rowsep0" align="char" char=".">67.98</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo CNS Availability of Compounds <b>6</b> and <b>32</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">matrix</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center" char=".">concn (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">concn (μM)</th><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">matrix</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center" char=".">concn (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">concn (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">960</td><td class="colsep0 rowsep0" align="char" char=".">2.06</td><td class="colsep0 rowsep0" align="char" char="."><b>32</b></td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">159</td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char="."><b>32</b></td><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">53.8</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">12.1</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">35.4</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">28.1</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic route to compound <b>6</b> shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The commercially available starting material <b>37</b> was subjected to Suzuki coupling conditions followed by ester hydrolysis to afford the carboxylic acid <b>38</b>. Compound <b>38</b> was then reacted with dimethyalmine hydrochloride and HATU to provide compound <b>6</b>. Compounds with an alkyl heterocyclic ring substituent were prepared by subjecting <b>37</b> to Buchwald–Hartwig coupling conditions using the desired amine (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). See <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> for the synthesis of triazole analogue <b>13</b> and <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> for the synthesis of diol and carboxylic acid analogues <b>22</b> and <b>24</b>.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Pyrazole Analogue <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 6 mol % Pd(dppf)Cl<sub>2</sub>, 8 mol % <i>t</i>-BuXphos, 5 equiv of 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 1 h, then 2 equiv of LiOH, H<sub>2</sub>O, rt; (b) 1.2 equiv of dimethylamine hydrochloride, 2 equiv of HATU, 5 equiv of DIEA, DMF, 54%.</p></p></figure><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Alkyl Heterocycle Analogue <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 6 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 9 mol % tris(<i>o</i>-tolyl)phosphine, 8 equiv of NaO-<i>t</i>-Bu, 1,4-dioxane, 110 °C, 2 h, 48%.</p></p></figure><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Triazole Analogue <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 5 mol % Pd(OAc)<sub>2</sub>, 12 mol % PPh<sub>3</sub>, 11 mol % CuI, Et<sub>2</sub>NH, 90 °C, 4 h, then 3 equiv of TBAF, THF, 4 h; (b) 1.5 equiv of TMS-N<sub>3</sub>, 5 mol % CuI, DMF, MeOH, 100 °C, 4 h, 36%.</p></p></figure><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diol and Carboxylic Acid Analogues <b>22</b> and <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 6 mol % Pd(dppf)Cl<sub>2</sub>, 8 mol % <i>t</i>-BuXphos, 5 equiv of 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 1 h; (b) 5 mol % AD-mix β, <i>t</i>-BuOH, H<sub>2</sub>O, 0 °C to rt, 12 h, 51%; (c) 1 mol % OSO<sub>4</sub>, 4 equiv of Oxone, rt, 6 h, 82%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By modifying the reported ALK inhibitor <b>1</b>, we have developed a novel ALK inhibitor that is extremely potent against the ALK G1202R mutant, which confers resistance to all clinical stage ALK inhibitors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In addition, <b>6</b> remains potent against the most common secondary ALK mutants and displays strong inhibitory effects across a panel of clinically relevant NSCLC cell lines with ALK mutations. Furthermore, compound <b>6</b> displayed good pharmacokinetic properties, suggesting the potential for this compound to be used in the treatment of NSCLC. From this study, we also identified compound <b>32</b>, which was slightly less potent against ALK G1202R and other secondary mutants, but displayed even stronger inhibitory effects in neuroblastoma cell lines.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting materials and other reagents were purchased from commercial suppliers and were used without further purification unless otherwise noted. All reactions were monitored by thin-layer chromatography (TLC) with 0.25 mm E. Merck precoated silica gel plates (60 F254) and a Waters LC/MS system (Waters 2489 UV/vis detector, Waters 3100 mass detector, Waters 515 HPLC pump, Waters 2545 binary gradient module, Waters reagent manager, Waters 2767 sample manager) using a SunFire C18 column (4.6 × 50 mm, 5 μm particle size): solvent gradient 100% A at 0 min, 1% A at 5 min; solvent A = 0.035% TFA in water; solvent B = 0.035% TFA in CH<sub>3</sub>CN; flow rate 2.5 mL/min. Purification of reaction products was carried out by flash chromatography using a CombiFlash Rf with a Teledyne Isco RediSep Rf Gold high-performance or Silicycle SiliaSep high-performance column (4, 12, 24, 40, 80, or 120 g). The purity of all compounds was over 95% and was analyzed with the Waters LC/MS system. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained using a Varian Inova-400 (400 MHz for <sup>1</sup>H and 75 MHz for <sup>13</sup>C) spectrometer. Chemical shifts are reported relative to chloroform (δ = 7.24) or dimethyl sulfoxide (δ = 2.50) for <sup>1</sup>H NMR and dimethyl sulfoxide (δ = 39.51) for <sup>13</sup>C NMR. Data are reported as br = broad, s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 9-Ethyl-6,6-dimethyl-8-(1-methyl-1<i>H</i>-pyrazol-4-yl)-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>7</b>)</h3><div class="NLM_p last">1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (34 mg, 0.16 mmol) and <b>37</b> (60 mg, 0.13 mmol) were dissolved in 1,4-dioxane (5 mL) and 2 M Na<sub>2</sub>CO<sub>3</sub> satd aq solution (0.17 mL, 0.34 mmol) and thoroughly degassed. Pd(dppf)Cl<sub>2</sub> (6 mg, 0.008 mmol) and <i>t</i>-Bu-XPhos (4 mg, 0.005 mmol) were added, and the mixture was heated to 100 °C in a sealed vial. After the mixture was stirred for 1 h, LC/MS analysis indicated the reaction was finished. The reaction mixture was filtered through Celite and purified by reversed-phase HPLC using a gradient of 30–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA to give the desired compound as a beige solid (33 mg, 61% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.75 (s, 1H), 8.35 (d, <i>J</i> = 8 Hz, 1H), 8.11 (s, 1H) 8.07 (s, 1H), 8.01 (S, 1H), 7.79 (d, <i>J</i> = 8 Hz, 2H), 7.63 (d, <i>J</i> = 8 Hz, 2H), 3.93 (s, 3H), 2.82 (q, <i>J</i> = 7.2 Hz, 2H) 1.79 (s, 6H), 1.17 (t, <i>J</i> = 7.2 Hz, 3H); MS <i>m</i>/<i>z</i> 395.73 [M + 1].</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(1<i>H</i>-pyrazol-4-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>8</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>8</b>. Purification by reversed-phase HPLC using a gradient of 40–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (21 mg, 41% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 13.6 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.11 (s, 1H) 8.01 (s, 1H), 7.97 (s, 1H), 7.78 (s, 1H), 7.60 (d, <i>J</i> = 7.2 Hz, 1H), 3.46 (br, 1H), 2.85 (q, <i>J</i> = 7.2 Hz, 2H) 1.79 (s, 6H), 1.22 (t, <i>J</i> = 7.2 Hz, 3H); MS <i>m</i>/<i>z</i> 381.65 [M + 1].</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(1<i>H</i>-pyrazol-3-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>9</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>9</b>. Purification by reversed-phase HPLC using a gradient of 40–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (25 mg, 48% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.78 (s, 1H), 8.33 (d, <i>J</i> = 8 Hz, 1H), 8.14 (s, 1H), 8.01 (d, <i>J</i> = 8 Hz, 2H), 7.83 (s, 1H), 7.76 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 6.89 (m, 1H), 2.81 (q, <i>J</i> = 8 Hz, 2H), 1.85 (s, 6H), 1.21 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 381.73 (M + 1).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 9-Ethyl-8-(isoxazol-4-yl)-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>10</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>10</b>. Purification by reversed-phase HPLC using a gradient of 30–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (31 mg, 60% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.87 (s, 1H), 9.25 (s, 1H), 9.02 (s, 1H), 8.31 (d, <i>J</i> = 8 Hz, 1H), 8.13 (s, 1H) 7.98 (s, 1H), 7.84 (S, 1H), 7.6 (d, <i>J</i> = 8 Hz, 1H), 2.75 (q, <i>J</i> = 7.2 Hz, 2H) 1.76 (s, 6H), 1.17 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i>: 382.43 [M + 1].</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 9-Ethyl-8-(furan-3-yl)-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>11</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>11</b>. Purification by reversed-phase HPLC using a gradient of 20–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (37 mg, 71% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.81 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.90, (s, 1H), 7.70 (s, 1H), 7.61 (d, <i>J</i> = 8 Hz, 1H), 7.43 (d, <i>J</i> = 8 Hz, 1H), 7.32 (d, <i>J</i> = 6 Hz, 1H), 2.81 (q, <i>J</i> = 8 Hz, 2H), 1.81 (s, 6H), 1.26 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 381.48 (M + 1).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(thiophene-2-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>12</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>12</b>. Purification by reversed-phase HPLC using a gradient of 20–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (31 mg, 58% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.78 (s, 1H), 8.36 (d, <i>J</i> = 8 Hz, 1H), 8.15 (s, 1H), 8.02 (s, 1H), 7.71 (m, 2H), 7.65 (m, 2H), 7.32 (d, <i>J</i> = 6 Hz, 1H), 2.81 (q, <i>J</i> = 8 Hz, 2H), 1.78 (s, 6H), 1.21 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 397.26 (M + 1).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(1<i>H</i>-1,2,3-triazol-5-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>13</b>)</h3><div class="NLM_p last">Ethnyltrimethylsilane (70 μL, 0.5 mmol) and <b>37</b> (200 mg, 0.45 mmol) were dissolved in diethylamine (2 mL). Triphenylphosphine (15 mg, 0.054 mmol) and CuI (10 mg, 0.05 mmol) were added, and the solution was degassed. Pd(OAc)<sub>2</sub> (5 mg, 0.022 mmol) was added and the mixture heated to 90 °C for 4 h. The mixture was filtered through Celite and purified by reversed-phase HPLC using a gradient of 40–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA to give the desired compound as a white solid (131 mg, 70% yield). This material was dissolved in THF (5 mL), and TBAF (1 M) in THF (0.95 mL, 0.95 mmol) was added. The mixture was stirred for 5 h at rt. The reaction was quenched with water, extracted with EtOAc (3 × 50 mL), washed with brine, dried over MgSO<sub>4</sub>, and condensed to give the alkyne as a white solid in quantitative yield. Trimethylsilyl azide (30 μL, 0.22 mmol) was added to a solution of the alkyne <b>39</b> (50 mg, 0.15 mmol) and CuI (3 mg, 0.007 mmol) in a 9:1 mixture of DMF/MeOH (1 mL), and the resulting mixture was stirred at 100 °C for 4 h. The mixture was filtered through Celite and purified by reversed-phase HPLC using a gradient of 40–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA to give the desired compound as a white solid (20 mg, 36% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 13.15 (s, 1H), 12.06 (br, 1H), 8.31 (d, <i>J</i> = 8 Hz, 1H), 8.11 (s, 1H) 8.04 (s, 1H), 7.95 (s, 1H), 7.71 (s, 1H), 7.60 (d, <i>J</i> = 7.2 Hz, 1H), 2.91 (q, <i>J</i> = 7.2 Hz, 2H) 1.81 (s, 6H), 1.17 (t, <i>J</i> = 7.2 Hz, 3H); MS <i>m</i>/<i>z</i> 382.19 [M + 1].</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(pyridin-4-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>14</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>14</b>. Purification by reversed-phase HPLC using a gradient of 20–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (27 mg, 50% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.88 (s, 1H), 8.85 (m, 2H), 8.36 (d, <i>J</i> = 8 Hz, 1H), 8.23 (s, 1H) 8.04 (s, 1H), 7.78 (s, 1H), 7.65 (d, <i>J</i> = 7.2 Hz, 1H), 2.70 (q, <i>J</i> = 8 Hz, 2H) 1.79 (s, 6H), 1.13 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 392.31 [M + 1].</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(pyridin-3-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>15</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>15</b>. Purification by reversed-phase HPLC using a gradient of 20–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (30 mg, 57% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.85 (s, 1H), 8.78 (m, 2H), 8.36 (d, <i>J</i> = 8 Hz, 1H), 8.22 (s, 1H), 8.13 (d, <i>J</i> = 8 Hz, 1H), 8.03 (s, 1H), 7.77 (s, 1H), 7.73 (m, 1H), 7.65 (d, <i>J</i> = 7.2 Hz, 1H), 2.66 (q, <i>J</i> = 8 Hz, 2H) 1.79 (s, 6H), 1.13 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 392.48 [M + 1].</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(pyrimidin-5-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>16</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>16</b>. Purification by reversed-phase HPLC using a gradient of 20–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (26 mg, 49% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.83 (s, 1H), 9.28 (s, 1H), 8.95 (s, 2H), 8.36 (d, <i>J</i> = 8 Hz, 1H), 8.22 (s, 1H), 8.03 (s, 1H), 7.84 (s, 1H), 7.64 (d, <i>J</i> = 7.2 Hz, 1H), 2.67 (q, <i>J</i> = 8 Hz, 2H) 1.8 (s, 6H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H); MS <i>m</i>/<i>z</i> 393.71 [M + 1].</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 8-(4-(Dimethylamino)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>17</b>)</h3><div class="NLM_p last"><i>N</i>,<i>N</i>-Dimethylpiperidin-4-amine (30 mg, 0.15 mmol), NaO-<i>t</i>-Bu (70 mg, 0.73 mmol), and <b>37</b> (40 mg, 0.09 mmol) were dissolved in 1,4-dioxane (3 mL), and the mixture was thoroughly degassed. Pd<sub>2</sub>(dba)<sub>3</sub> (5 mg, 0.05 mmol) and tris(<i>o</i>-tolyl)phosphine (3 mg, 0.09 mmol) were added. The mixture was heated to 110 °C for 4 h. LC/MS analysis showed conversion to the desired product. The mixture was filtered and purified by reversed-phase HPLC using a gradient of 10–60% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA to give the desired compound as a brown solid (18 mg, 45% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.76 (s, 1H), 8.31 (d, <i>J</i> = 8 Hz, 2H), 8.04 (s, 1H) 7.98 (s, 1H), 7.58 (d, <i>J</i> = 8 Hz, 1H), 7.34 (s, 1H), 6.51 (s, 1H), 4.07 (m, 4H), 2.80 (s, 6H), 3.14 (m, 4H), 2.71 (q, <i>J</i> = 7.2 Hz, 2H) 1.74 (s, 6H), 1.23 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 382.43 [M + 1].</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(piperazin-1-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>18</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>17</b> was used to prepare compound <b>18</b>. Purification by reversed-phase HPLC using a gradient of 10–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (13 mg, 36% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.81 (s, 1H), 8.29 (d, <i>J</i> = 8 Hz, 1H), 8.06 (s, 1H) 7.98 (s, 1H), 7.59 (d, <i>J</i> = 7 Hz, 1H), 7.35 (s, 1H), 3.14 (m, 4H), 2.71 (q, <i>J</i> = 7.2 Hz, 2H), 2.49 (m, 4H), 1.74 (s, 6H), 1.25 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 399.69 [M + 1].</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 9-Ethyl-6,6-dimethyl-8-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>19</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>17</b> was used to prepare compound <b>19</b>. Purification by reversed-phase HPLC using a gradient of 10–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (11 mg, 28% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.75 (s, 1H), 8.27 (d, <i>J</i> = 8 Hz, 1H), 8.06 (s, 1H) 7.96 (s, 1H), 7.58 (d, <i>J</i> = 7 Hz, 1H), 7.35 (s, 1H), 3.21 (m, 4H), 2.71 (q, <i>J</i> = 7.2 Hz, 2H), 2.10 (m, 4H), 1.76 (s, 6H), 1.17 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 413.27 [M + 1].</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 9-Ethyl-6,6-dimethyl-8-morpholino-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>20</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>17</b> was used to prepare compound <b>20</b>. Purification by reversed-phase HPLC using a gradient of 10–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (14 mg, 38% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.76 (s, 1H), 8.31 (d, <i>J</i> = 8 Hz, 1H), 8.02 (s, 1H) 7.97 (s, 1H), 7.76 (d, <i>J</i> = 8 Hz, 1H), 7.58 (s, 1H), 7.34 (S, 1H), 3.78 (m, 2H), 2.98 (m, 2H) 2.71 (q, <i>J</i> = 7.2 Hz, 2H) 1.76 (s, 6H), 1.23 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 400.49 [M + 1].</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 9-Ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3,8-dicarbonitrile (<b>21</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>17</b> was used to prepare compound <b>21</b>. Purification by reversed-phase HPLC using a gradient of 20–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (14 mg, 45% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.92 (s, 1H), 8.44 (s, 1H), 8.33 (d, <i>J</i> = 8 Hz, 1H), 8.24 (s, 1H) 8.05 (s, 1H), 7.66 (d, <i>J</i> = 8 Hz, 1H), 2.92 (q, <i>J</i> = 7.2 Hz, 2H), 1.79 (s, 6H), 1.31 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 340.53 [M + 1].</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 9-Ethyl-6,6-dimethyl-11-oxo-8-vinyl-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>40</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>40</b> (32 mg, 68% yield).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>R</i>)-8-(1,2-Dihydroxyethyl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>22</b>)</h3><div class="NLM_p last">AD-mix β (206 mg) and <b>40</b> (50 mg, 0.15 mmol) were dissolved in a 0 °C solution of H<sub>2</sub>O (3 mL) and <i>t</i>-BuOH. The mixture was slowly warmed to rt and stirred for 12 h at rt. LC/MS analysis showed complete conversion of the starting material to the desired product. The reaction mixture was filtered and purified by reversed-phase HPLC using a gradient of 20–70% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA to give the desired compound as a white solid (28 mg, 51% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.75 (s, 1H), 8.32 (d, <i>J</i> = 8 Hz, 1H), 7.99 (m, 2H), 7.85 (s, 1H), 7.63 (d, <i>J</i> = 8 Hz, 1H), 5.38 (d, <i>J</i> = 4 Hz, 1H), 4.87 (m, 2H), 3.48 (m, 2H), 2.75 (m, 2H), 1.75 (s, 6H), 1.25 (t, <i>J</i> = 7 Hz, 3H); MS <i>m</i>/<i>z</i> 375.74 [M + 1].</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-8-(1,2-Dihydroxyethyl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>23</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>22</b> was used to prepare compound <b>23</b> using AD-mix α instead of AD-mix β. Purification by reversed-phase HPLC using a gradient of 20–70% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a white solid (24 mg, 44% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.82 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.03 (m, 2H), 7.85 (s, 1H), 7.63 (d, <i>J</i> = 8 Hz, 1H), 5.40 (d, <i>J</i> = 4 Hz, 1H), 4.78 (m, 2H), 3.69 (m, 2H), 2.68 (m, 2H), 1.81 (s, 6H), 1.13 (t, <i>J</i> = 7 Hz, 3H); MS <i>m</i>/<i>z</i> 375.68 [M + 1].</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-8-carboxylic Acid (<b>24</b>)</h3><div class="NLM_p last">Compound <b>40</b> (333 mg, 0.98 mmol) was dissolved in DMF (5 mL). OsO<sub>4</sub> (2.5%) in <i>t</i>-BuOH (100 μL, 0.01 mmol) was added, and the resulting mixture was stirred for 5 min. Oxone (2.4 g, 3.9 mmol) was added, and the resulting mixture was stirred for 6 h. LC/MS analysis showed the reaction was complete. Na<sub>2</sub>SO<sub>3</sub> satd aq solution (50 mL) was added, and the resulting mixture was stirred for 1 h. The reaction was partitioned between EtOAc and 1 M HCl, extracted with EtOAc, washed with brine, and condensed. Purification by reversed-phase HPLC using a gradient of 20–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (285 mg, 82% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.89 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.13 (d, <i>J</i> = 8 Hz, 2H), 8.03 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 2.98 (q, <i>J</i> = 7.2 Hz, 2H) 1.76 (s, 6H), 1.23 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 359.43 [M + 1].</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-9-Ethyl-6,6-dimethyl-8-(3-morpholinoprop-1-en-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>25</b>)</h3><div class="NLM_p last">(<i>E</i>)-(3-Chloroprop-1-en-1-yl)boronic acid (42 mg, 0.34 mmol) and <b>37</b> (100 mg, 0.23 mmol) were dissolved in DMF (5 mL). Cs<sub>2</sub>CO<sub>3</sub> (370 mg, 1.14 mmol) was added and the mixture thoroughly degassed. Pd(dppf)Cl<sub>2</sub> (17 mg, 0.02 mmol) was added and the mixture heated to 100 °C for 1 h. LC/MS analysis showed conversion of the starting material to the desired product. The mixture was cooled to rt, and morpholine (60 μL, 0.68 mmol) was added. The mixture was stirred at rt for 2 h. LC/MS analysis showed conversion to the desired product. The mixture was filtered and purified by reversed-phase HPLC using a gradient of 10–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA to give the desired compound as a brown solid (56 mg, 56% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.82 (s, 1H), 8.30 (d, <i>J</i> = 8 Hz, 1H), 8.03 (m, 3H), 8.03 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 7.19 (d, <i>J</i> = 16 Hz, 1H), 6.48 (m, 1H), 3.99 (m, 4H), 2.80 (q, <i>J</i> = 8 Hz, 2H) 1.79 (s, 6H), 1.20 (t, <i>J</i> = 7.2 Hz, 3H); MS <i>m</i>/<i>z</i> 440.84 [M + 1].</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 9-Ethyl-8-(6-hydroxypyridin-3-yl)-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>26</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>26</b>. Purification by reversed-phase HPLC using a gradient of 10–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (33 mg, 60% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.88 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.18 (s, 1H), 8.06 (d, <i>J</i> = 7 Hz, 2H), 7.98 (d, <i>J</i> = 8 Hz, 1H), 7.89 (br, 1H), 7.73 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 7.03 (d, <i>J</i> = 8 Hz, 1H), 2.68 (q, <i>J</i> = 7.2 Hz, 2H), 1.78 (s, 6H), 1.18 (t, <i>J</i> = 7 Hz, 3H); MS <i>m</i>/<i>z</i> 408.29 [M + 1].</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 8-(6-Aminopyridin-3-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>27</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>27</b>. Purification by reversed-phase HPLC using a gradient of 10–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (28 mg, 50% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.78 (s, 1H), 11.84 (br, 1H), 8.36 (d, <i>J</i> = 8 Hz, 1H), 8.14 (s, 1H), 7.67 (s, 1H), 7.63 (d, <i>J</i> = 8 Hz, 1H), 7.55 (d, <i>J</i> = 7.2 Hz, 1H), 7.46 (s, 1H), 6.46 (d, <i>J</i> = 8.2 Hz, 1H), 2.69 (q, <i>J</i> = 8 Hz, 2H), 1.78 (s, 6H), 1.17 (t, <i>J</i> = 7 Hz, 3H); MS <i>m</i>/<i>z</i> 407.72 [M + 1].</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 8-((2-(Dimethylamino)ethyl)methylamino)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>28</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>17</b> was used to prepare compound <b>28</b>. Purification by reversed-phase HPLC using a gradient of 20–90% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (12 mg, 32% yield): <sup>1</sup>HNMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.78 (br, 1H), 8.29 (d, <i>J</i> = 4 Hz, 1H), 8.05 (s, 1H), 7.99 (s, 1H), 7.58 (d, <i>J</i> = 7.2 Hz, 1H), 7.47 (s, 1H), 2.8 (s, 3H), 2.73 (m, 5H), 2.48 (s, 6H), 2.73 (m, 5H), 1.79 (s, 6H), 0.88 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 415.33 (M + 1).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>29</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>29</b>. Purification by reversed-phase HPLC using a gradient of 10–80% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (48 mg, 76% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.76 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.18 (s, 1H), 8.11 (s, 1H), 8.01 (s, 1H), 7.78 (d, <i>J</i> = 8 Hz, 2H), 7.62 (d, <i>J</i> = 8 Hz, 1H), 4.49 (q, <i>J</i> = 7.2 Hz, 1H), 3.98 (m, 4H), 3.50 (m, 4H), 2.85 (q, <i>J</i> = 7.2 Hz, 2H), 1.76 (s, 6H), 1.23 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 465.84 [M + 1].</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>30</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>30</b>. Purification by reversed-phase HPLC using a gradient of 30–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (38 mg, 60% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.82 (s, 1H), 8.33 (d, <i>J</i> = 8 Hz, 1H), 8.13 (d, <i>J</i> = 8 Hz, 2H), 8.03 (S, 1H), 7.87 (s, 1H), 7.79 (s, 1H), 7.63 (d, <i>J</i> = 8 Hz, 2H), 4.59 (m, 1H), 3.47 (m, 2H), 3.13 (m, 2H), 2.85 (q, <i>J</i> = 7.2 Hz, 2H), 2.26 (m, 4H), 1.79 (s, 6H), 1.23 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 464.47 [M + 1].</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 8-(1-(2-(Dimethylamino)ethyl)-1<i>H</i>-pyrazol-4-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>31</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>31</b>. Purification by reversed-phase HPLC using a gradient of 30–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (29 mg, 48% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.83 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.22 (s, 1H), 8.14 (s, 1H), 8.03 (s, 1H), 7.95 (s, 1H), 7.78 (s, 1H), 7.63 (d, <i>J</i> = 8 Hz, 1H), 4.21 (m, 2H), 3.65 (m, 2H), 2.86 (s, 6H), 1.79 (s, 6H), 1.24 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 452.57 (M + 1).</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 8-(1-(3-(Dimethylamino)propyl)-1<i>H</i>-pyrazol-4-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>32</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>32</b>. Purification by reversed-phase HPLC using a gradient of 30–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (31 mg, 49% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 13.05 (s, 1H), 8.36 (d, <i>J</i> = 8 Hz, 1H), 8.18 (s, 1H), 8.11 (S, 1H), 8.15 (s, 1H), 8.06 (s, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 7.62 (d, <i>J</i> = 8 Hz, 1H), 4.32 (m, 2H), 3.15 (m, 2H), 2.86 (m, 5H), 2.27 (m, 2H), 1.83 (s, 6H), 1.26 (t, <i>J</i> = 8 Hz, 3H); <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 179.61, 160.69, 150.93, 146.15, 139.55, 139.25, 136.12, 136.26, 130.09, 128.13, 127.41, 126.17, 125.25, 122.09, 120.52, 116.95, 109.94, 105.11, 54.78, 48.95, 42.70, 36.75, 30.35, 26.31, 25.38, 15.20; MS <i>m</i>/<i>z</i> 466.37 [M + 1].</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-methylacetamide (<b>33</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>33</b>. Purification by reversed-phase HPLC using a gradient of 20–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (27 mg, 44% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.87 (s, 1H), 8.51 (s, 1H), 8.31 (d, <i>J</i> = 8 Hz, 1H), 8.13 (d, <i>J</i> = 8 Hz, 2H), 8.02 (s, 1H), 7.86 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 6.43 (s, 1H), 5.32 (s, 2H), 3.27 (s, 3H), 2.83 (q, <i>J</i> = 8 Hz, 2H), 1.80 (s, 6H), 1.22 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 452.59 [M + 1].</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>,<i>N</i>-dimethylacetamide (<b>6</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>6</b>. Purification by reversed-phase HPLC using a gradient of 20–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (34 mg, 54% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.77 (s, 1H), 8.57 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.13 (d, <i>J</i> = 8 Hz, 2H), 8.02 (s, 1H), 7.86 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 5.21 (s, 2H), 3.01 (s, 3H), 2.89 (s, 3H), 2.83 (q, <i>J</i> = 8 Hz, 2H), 1.80 (s, 6H), 1.22 (t, <i>J</i> = 8 Hz, 3H); <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 179.61, 167.01, 160.63, 147.78, 146.10, 139.58, 138.93, 136.61, 136.16, 131.37, 129.83, 128.13, 127.3, 126.22, 125.33, 122.09, 120.42, 116.85, 109.97, 105.15, 53.34, 36.74, 36.36, 35.68, 30.39, 26.32, 15.27; MS <i>m</i>/<i>z</i> 466.19 [M + 1].</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)-1<i>H</i>-pyrazol-1-yl)acetamide (<b>34</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>34</b>. Purification by reversed-phase HPLC using a gradient of 20–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (24 mg, 40% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.86 (s, 1H), 8.63 (S, 1H), 8.25 (d, <i>J</i> = 8 Hz, 1H), 8.08 (d, <i>J</i> = 8 Hz, 2H), 7.96 (s, 1H), 7.87 (S, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 5.31 (s, 2H), 2.87 (q, <i>J</i> = 8 Hz, 2H), 1.77 (s, 6H), 1.18 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 438.59 [M + 1].</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>,<i>N</i>,2-trimethylpropanamide (<b>35</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>35</b>. Purification by reversed-phase HPLC using a gradient of 10–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (38 mg, 57% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.76 (s, 1H), 8.33 (d, <i>J</i> = 8 Hz, 1H), 8.22 (s, 1H), 8.11 (s, 1H), 8.02 (s, 1H), 7.87 (s, 1H), 7.82 (s, 1H), 7.64 (d, <i>J</i> = 8 Hz, 1H), 2.85 (q, <i>J</i> = 8 Hz, 2H), 1.81 (s, 6H), 1.77 (s, 6H), 1.19 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 494.61 (M + 1).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)-<i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-pyrazole-1-carboxamide (<b>36</b>)</h3><div class="NLM_p last">The procedure used to prepare compound <b>7</b> was used to prepare compound <b>36</b>. Purification by reversed-phase HPLC using a gradient of 20–100% CH<sub>3</sub>CN/H<sub>2</sub>O with 0.035% TFA gave the desired compound as a beige solid (31 mg, 51% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 12.77 (s, 1H), 8.52 (s, 1H), 8.34 (d, <i>J</i> = 8 Hz, 1H), 8.13 (d, <i>J</i> = 8 Hz, 2H), 8.02 (s, 1H), 7.86 (s, 1H), 7.63 (d, <i>J</i> = 8 Hz, 1H), 2.83 (q, <i>J</i> = 8 Hz, 2H), 2.51 (s, 6H), 1.85 (s, 6H), 1.22 (t, <i>J</i> = 8 Hz, 3H); MS <i>m</i>/<i>z</i> 452.68 [M + 1].</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01136">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01136" class="ext-link">10.1021/acs.jmedchem.5b01136</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Ba/F3 cellular IC<sub>50</sub> curves for crizotinib, ceritinib, alectinib, and compound <b>6</b>, cellular IC<sub>50</sub> curves for patient-derived NSCLC cells and neuroblastoma cells for compound <b>6</b>, cellular IC<sub>50</sub> values with standard deviations for crizotinib, ceritinib, alectinib, and compound <b>6</b>, and full Ambit profiling for compounds <b>6</b> and <b>32</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Simplified molecular-input line-entry system (SMILES) data for compounds <b>6</b>–<b>36</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf">jm5b01136_si_001.pdf (1.46 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_002.csv">jm5b01136_si_002.csv (3.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01136" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathanael S. Gray</span> - <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a6e8c7d2cec7c8c7c3caf9e1d4c7dfe6c2c0c5cf88cec7d4d0c7d4c288c3c2d3"><span class="__cf_email__" data-cfemail="2d634c59454c434c4841726a5f4c546d494b4e4403454c5f5b4c5f4903484958">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Hatcher</span> - <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magda Bahcall</span> - <span class="hlFld-Affiliation affiliation">†Department
of Cancer Biology, ‡Lowe Center for Thoracic Oncology, and §Belfer Center
for Applied Cancer Science, Dana-Farber
Cancer Institute, 450
Brookline Avenue, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pediatric Haematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology, Seoul 136-791, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, 145 Anam-ro, Seongbuk-gu, Seoul 136-713, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hwan Geun Choi</span> - <span class="hlFld-Affiliation affiliation">†Department
of Cancer Biology, ‡Lowe Center for Thoracic Oncology, and §Belfer Center
for Applied Cancer Science, Dana-Farber
Cancer Institute, 450
Brookline Avenue, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pediatric Haematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology, Seoul 136-791, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, 145 Anam-ro, Seongbuk-gu, Seoul 136-713, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Gao</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatric Haematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taebo Sim</span> - <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology, Seoul 136-791, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, 145 Anam-ro, Seongbuk-gu, Seoul 136-713, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rani George</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatric Haematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pasi A. Jänne</span> - <span class="hlFld-Affiliation affiliation">†Department
of Cancer Biology, ‡Lowe Center for Thoracic Oncology, and §Belfer Center
for Applied Cancer Science, Dana-Farber
Cancer Institute, 450
Brookline Avenue, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pediatric Haematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology, Seoul 136-791, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, 145 Anam-ro, Seongbuk-gu, Seoul 136-713, Korea</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.M.H. and M.B. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d145e4641-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding for this work was received from the National Institutes of Health (NIH) (Grant R01 CA136851-07) (P.A.J. and N.S.G.) and the creative/challenging research program of the National Research Foundation of Korea (Grant NRF-2011-0028676)</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">This paper was published ASAP on November 25, 2015. Schemes 1–4 were updated. The revised paper was reposted on December 10, 2015.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> Abbreviations</h2><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">ALKi</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase inhibitor</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleoplasmin</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">IMT</td><td class="NLM_def"><p class="first last">microfibroblastic tumor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. P.</span><span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">2175</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span><span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&issue=18&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+L.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%2BL.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26issue%3D18%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bilsland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mead, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Znamenskiy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz-Sanjuan, I.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/sj.npp.1301446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fsj.npp.1301446" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=685-700&issue=3&author=J.+G.+Bilslandauthor=A.+Wheeldonauthor=A.+Meadauthor=P.+Znamenskiyauthor=S.+Almondauthor=K.+A.+Watersauthor=M.+Thakurauthor=V.+Beaumontauthor=T.+P.+Bonnertauthor=R.+Heavensauthor=P.+Whitingauthor=G.+McAllisterauthor=I.+Munoz-Sanjuan&title=Behavioral+and+neurochemical+alterations+in+mice+deficient+in+anaplastic+lymphoma+kinase+suggest+therapeutic+potential+for+psychiatric+indications&doi=10.1038%2Fsj.npp.1301446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301446%26sid%3Dliteratum%253Aachs%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DZnamenskiy%26aufirst%3DP.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DThakur%26aufirst%3DM.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DBonnert%26aufirst%3DT.%2BP.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DBehavioral%2520and%2520neurochemical%2520alterations%2520in%2520mice%2520deficient%2520in%2520anaplastic%2520lymphoma%2520kinase%2520suggest%2520therapeutic%2520potential%2520for%2520psychiatric%2520indications%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26issue%3D3%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fsj.npp.1301446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1056/NEJMoa1006448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&issue=18&author=E.+L.+Kwakauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=B.+Solomonauthor=R.+G.+Makiauthor=S.+H.+I.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+Janneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.+H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+Lymphoma+Kinase+Inhibition+in+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1006448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0lg5wbSTBXh-Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520Inhibition%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D18%26spage%3D1693%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1006448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Lebeau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doane, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardiman, J. W.</span><span> </span><span class="NLM_article-title">The T(2–5)(P23-Q35) - A Recurring Chromosomal Abnormality in KI-1-Positive Anaplastic Large Cell Lymphoma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">870</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1989&pages=866-870&issue=12&author=M.+M.+Lebeauauthor=M.+A.+Bitterauthor=R.+A.+Larsonauthor=L.+A.+Doaneauthor=E.+D.+Ellisauthor=W.+A.+Franklinauthor=C.+M.+Rubinauthor=M.+E.+Kadinauthor=J.+W.+Vardiman&title=The+T%282%E2%80%935%29%28P23-Q35%29+-+A+Recurring+Chromosomal+Abnormality+in+KI-1-Positive+Anaplastic+Large+Cell+Lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLebeau%26aufirst%3DM.%2BM.%26aulast%3DBitter%26aufirst%3DM.%2BA.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DDoane%26aufirst%3DL.%2BA.%26aulast%3DEllis%26aufirst%3DE.%2BD.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DRubin%26aufirst%3DC.%2BM.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520T%25282%25E2%2580%25935%2529%2528P23-Q35%2529%2520-%2520A%2520Recurring%2520Chromosomal%2520Abnormality%2520in%2520KI-1-Positive%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%26jtitle%3DLeukemia%26date%3D1989%26volume%3D3%26issue%3D12%26spage%3D866%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&issue=12&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26issue%3D12%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehner, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, D. A.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor - A comparative immunohistochemical study</span> <span class="citation_source-journal">Am. J. Surg. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1364</span><span class="NLM_x">–</span> <span class="NLM_lpage">1371</span><span class="refDoi"> DOI: 10.1097/00000478-200111000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1097%2F00000478-200111000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=11684952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A280%3ADC%252BD3MnkvVehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=1364-1371&issue=11&author=J.+R.+Cookauthor=L.+P.+Dehnerauthor=M.+H.+Collinsauthor=Z.+G.+Maauthor=S.+W.+Morrisauthor=C.+M.+Coffinauthor=D.+A.+Hill&title=Anaplastic+lymphoma+kinase+%28ALK%29+expression+in+the+inflammatory+myofibroblastic+tumor+-+A+comparative+immunohistochemical+study&doi=10.1097%2F00000478-200111000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study</span></div><div class="casAuthors">Cook J R; Dehner L P; Collins M H; Ma Z; Morris S W; Coffin C M; Hill D A</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1364-71</span>
        ISSN:<span class="NLM_cas:issn">0147-5185</span>.
    </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is an uncommon mesenchymal neoplasm with a variable histologic appearance that may mimic other spindle cell processes, particularly nodular fasciitis, desmoid tumor, and in intra-abdominal locations, gastrointestinal stromal tumor.  Recently, gene fusions involving ALK at chromosome 2p23 have been described in IMTs.  The resultant ALK protein overexpression in the myofibroblastic component of these tumors is detectable by immunohistochemistry.  We examined 73 IMTs, 20 cases of nodular fasciitis, 15 desmoid fibromatoses, and 15 gastrointestinal stromal tumors by immunohistochemistry using ALK-11, a rabbit polyclonal antibody that recognizes the C-terminus of the protein.  ALK positivity was detected in 44 of 73 (60%) IMTs.  All cases of nodular fasciitis, desmoid fibromatosis, and gastrointestinal stromal tumors were ALK negative (p < 0.001).  These findings demonstrate that ALK positivity is common in IMTs, and immunohistochemistry using anti-ALK antibodies can be helpful in the differential diagnosis of these neoplasms.  In addition, anti-ALK staining seems to correlate with those IMTs that have the typical tri-patterned histologic appearance and clinical presentation, providing additional support to the premise that IMT is a distinctive clinicopathologic entity within the broad category of inflammatory pseudotumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8OlyInGEWUlw2ofyr07jXfW6udTcc2eZPWtqGKQEiU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnkvVehtw%253D%253D&md5=6875da498f3a364ebac2a2d8971798dd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2F00000478-200111000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000478-200111000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DDehner%26aufirst%3DL.%2BP.%26aulast%3DCollins%26aufirst%3DM.%2BH.%26aulast%3DMa%26aufirst%3DZ.%2BG.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DCoffin%26aufirst%3DC.%2BM.%26aulast%3DHill%26aufirst%3DD.%2BA.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520expression%2520in%2520the%2520inflammatory%2520myofibroblastic%2520tumor%2520-%2520A%2520comparative%2520immunohistochemical%2520study%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2001%26volume%3D25%26issue%3D11%26spage%3D1364%26epage%3D1371%26doi%3D10.1097%2F00000478-200111000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Subero, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestou, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auvigne, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delsol, G.</span><span> </span><span class="NLM_article-title">ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2568</span><span class="NLM_x">–</span> <span class="NLM_lpage">2573</span><span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&issue=7&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+Muller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+diffuse+large+B-cell+lymphoma+is+associated+with+Clathrin-ALK+rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520diffuse%2520large%2520B-cell%2520lymphoma%2520is%2520associated%2520with%2520Clathrin-ALK%2520rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26issue%3D7%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Jazii, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najafi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malekzadeh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrads, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziaee, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abnet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazdznbod, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karkhane, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salekdeh, G. H.</span><span> </span><span class="NLM_article-title">Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">44</span><span class="NLM_x">) </span> <span class="NLM_fpage">7104</span><span class="NLM_x">–</span> <span class="NLM_lpage">7112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.3748%2Fwjg.v12.i44.7104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=17131471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=7104-7112&issue=44&author=F.+R.+Jaziiauthor=Z.+Najafiauthor=R.+Malekzadehauthor=T.+P.+Conradsauthor=A.+A.+Ziaeeauthor=C.+Abnetauthor=M.+Yazdznbodauthor=A.+A.+Karkhaneauthor=G.+H.+Salekdeh&title=Identification+of+squamous+cell+carcinoma+associated+proteins+by+proteomics+and+loss+of+beta+tropomyosin+expression+in+esophageal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer</span></div><div class="casAuthors">Jazii, Ferdous Rastgar; Najafi, Zahra; Malekzadeh, Reza; Conrads, Thomas P.; Ziaee, Abed Ali; Abnet, Christian; Yazdznbod, Mansour; Karkhane, Ali Asghar; Salekdeh, Ghasem H.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">7104-7112</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">To assess the proteome of normal vs. tumor tissue in squamous cell carcinoma of the esophagus (SCCE) in Iranian patients and compare our results with former reports by using proteomics.  Protein was extd. from normal and tumor tissues.  Two dimensional electrophoresis was carried out and spots with differential expression were identified with mass spectrometry.  RNA extn. and RT-PCR along with immunodetection were performed.  Fourteen proteins were found whose expression levels differed in tumor compared to normal tissues.  Mass spectrometric anal. resulted in the identification of β-tropomyosin (TMβ), myosin light chain 2 (and its isoform), myosin regulatory light chain 2, peroxyredoxin 2, annexin I and an unknown polypeptide as the down regulated polypeptides in tumor tissue.  Heat shock protein 70 (HSP70), TPM4-ALK fusion oncoprotein 2, myosin light polypeptide 6, keratin I, GH16431p and calreticulin were the up-regulated polypeptides found in tumor tissue.  Several of these proteins, such as TMβ, HSP70, annexin I, calreticulin, TPM4-ALK and isoforms of myosins, have been well recognized in tumorigenesis of esophageal or other types of cancers.  The study not only supports the involvement of some of the formerly reported proteins in SCCE but also introduces addnl. proteins found to be lost in SCCE, including TMβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQBiL27ZRH7Vg90H21EOLACvtfcHk0lhjo3tp2iumtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D&md5=2de4e4dc1639b4414afa8ea6e072c22c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v12.i44.7104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v12.i44.7104%26sid%3Dliteratum%253Aachs%26aulast%3DJazii%26aufirst%3DF.%2BR.%26aulast%3DNajafi%26aufirst%3DZ.%26aulast%3DMalekzadeh%26aufirst%3DR.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DZiaee%26aufirst%3DA.%2BA.%26aulast%3DAbnet%26aufirst%3DC.%26aulast%3DYazdznbod%26aufirst%3DM.%26aulast%3DKarkhane%26aufirst%3DA.%2BA.%26aulast%3DSalekdeh%26aufirst%3DG.%2BH.%26atitle%3DIdentification%2520of%2520squamous%2520cell%2520carcinoma%2520associated%2520proteins%2520by%2520proteomics%2520and%2520loss%2520of%2520beta%2520tropomyosin%2520expression%2520in%2520esophageal%2520cancer%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2006%26volume%3D12%26issue%3D44%26spage%3D7104%26epage%3D7112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x"> (</span><span class="NLM_issue">7153</span><span class="NLM_x">) </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">U3</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-U3&issue=7153&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+I.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0liFc9Nk03Y57w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%2BI.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26issue%3D7153%26spage%3D561%26epage%3DU3%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x"> (</span><span class="NLM_issue">7215</span><span class="NLM_x">) </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">U51</span><span class="refDoi"> DOI: 10.1038/nature07398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-U51&issue=7215&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma&doi=10.1038%2Fnature07398"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26issue%3D7215%26spage%3D967%26epage%3DU51%26doi%3D10.1038%2Fnature07398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provide a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x"> (</span><span class="NLM_issue">7215</span><span class="NLM_x">) </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1038/nature07397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnature07397" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&issue=7215&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+M.+Zhangauthor=Y.+Ahnauthor=W.+J.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Q.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provide+a+therapeutic+target+in+neuroblastoma&doi=10.1038%2Fnature07397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature07397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07397%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%2BM.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%2BQ.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provide%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26issue%3D7215%26spage%3D975%26epage%3D978%26doi%3D10.1038%2Fnature07397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The ALK Inhibitor ceritinib Overcomes crizotinib Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">673</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&issue=6&author=L.+Fribouletauthor=N.+X.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.+Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Y.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+Inhibitor+ceritinib+Overcomes+crizotinib+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0lhPrRaVpumrKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%2BX.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%2BY.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520Inhibitor%2520ceritinib%2520Overcomes%2520crizotinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D6%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekhail, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tursi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span> </span><span class="NLM_article-title">First-Line crizotinib versus Chemotherapy in ALK-Positive Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2177</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1408440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25470694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2167-2177&issue=23&author=B.+J.+Solomonauthor=T.+Mokauthor=D.+W.+Kimauthor=Y.+L.+Wuauthor=K.+Nakagawaauthor=T.+Mekhailauthor=E.+Felipauthor=F.+Cappuzzoauthor=J.+Paoliniauthor=T.+Usariauthor=S.+Iyerauthor=A.+Reismanauthor=K.+D.+Wilnerauthor=J.+Tursiauthor=F.+Blackhall&title=First-Line+crizotinib+versus+Chemotherapy+in+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1408440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span></div><div class="casAuthors">Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2167-2177/1-2167-2177/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with std. chemotherapy as first-line treatment for advanced ALK-pos. non-small-cell lung cancer (NSCLC) is unknown.  METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-pos. nonsquamous NSCLC who had received no previous systemic treatment for advanced disease.  Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive i.v. chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per mL per min) every 3 wk for up to six cycles.  Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy.  The primary end point was progression-free survival as assessed by independent radiol. review.  RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 mo vs. 7.0 mo; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).  Objective response rates were 74% and 45 %, resp. (P<0.001).  Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-yr survival was 84% with crizotinib and 79% with chemotherapy.  The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.  As compared with chemotherapy, crizotinib was assocd. with greater redn. in lung cancer symptoms and greater improvement in quality of life.  CONCLUSIONS Crizotinib was superior to std. first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7N7XM7ywBLVg90H21EOLACvtfcHk0lhPrRaVpumrKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D&md5=afd3c75ef95aff5c0fa12b6b7e22b46a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408440%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPaolini%26aufirst%3DJ.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DReisman%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DTursi%26aufirst%3DJ.%26aulast%3DBlackhall%26aufirst%3DF.%26atitle%3DFirst-Line%2520crizotinib%2520versus%2520Chemotherapy%2520in%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D23%26spage%3D2167%26epage%3D2177%26doi%3D10.1056%2FNEJMoa1408440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Byrne, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro-Sibilot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tassell, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2394</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&issue=25&author=A.+T.+Shawauthor=D.+W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crinoauthor=M.+J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.+L.+Wuauthor=M.+Thomasauthor=K.+J.+O%27Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+Janne&title=crizotinib+versus+Chemotherapy+in+Advanced+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0lhPrRaVpumrKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%2527Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3Dcrizotinib%2520versus%2520Chemotherapy%2520in%2520Advanced%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26issue%3D25%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25322323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=429-439&issue=7&author=M.+M.+Awadauthor=A.+T.+Shaw&title=ALK+Inhibitors+in+Non-Small+Cell+Lung+Cancer%3A+Crizotinib+and+Beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: crizotinib and beyond</span></div><div class="casAuthors">Awad Mark M; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">429-39</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.  Resistance to crizotinib invariably develops, however, through a variety of mechanisms.  In the last few years, a flurry of new and more potent ALK inhibitors has emerged for the treatment of ALK-positive NSCLC, including ceritinib (LDK378), alectinib (RO5424802/CH5424802), AP26113, ASP3026, TSR-011, PF-06463922, RXDX-101, X-396, and CEP-37440.  Cancers harboring ALK rearrangements may also be susceptible to treatment with heat shock protein 90 inhibitors.  This review focuses on the pharmacologic and clinical properties of these compounds, either as monotherapies or in combination with other drugs.  With so many ALK inhibitors in development, the challenges of how these agents should be studied and ultimately prescribed are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTc4MrEK-FRv9pSBfyDvp7fW6udTcc2eYTCfxt08gYj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D&md5=ae4655774258c9265a283749559ac393</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520Inhibitors%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Crizotinib%2520and%2520Beyond%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D12%26issue%3D7%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltshire, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span> </span><span class="NLM_article-title">Clinical Experience With crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">1881</span><span class="NLM_x">–</span> <span class="NLM_lpage">U41</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.0539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1200%2FJCO.2014.59.0539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25624436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1881-U41&issue=17&author=D.+B.+Costaauthor=A.+T.+Shawauthor=S.+H.+I.+Ouauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=M.+J.+Ahnauthor=C.+C.+Zhouauthor=M.+Shreeveauthor=P.+Selaruauthor=A.+Polliauthor=P.+Schnellauthor=K.+D.+Wilnerauthor=R.+Wiltshireauthor=D.+R.+Camidgeauthor=L.+Crino&title=Clinical+Experience+With+crizotinib+in+Patients+With+Advanced+ALK-Rearranged+Non-Small-Cell+Lung+Cancer+and+Brain+Metastases&doi=10.1200%2FJCO.2014.59.0539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</span></div><div class="casAuthors">Costa, Daniel B.; Shaw, Alice T.; Ou, Sai-Hong I.; Solomon, Benjamin J.; Riely, Gregory J.; Ahn, Myung-Ju; Zhou, Caicun; Shreeve, S. Martin; Selaru, Paulina; Polli, Anna; Schnell, Patrick; Wilner, Keith D.; Wiltshire, Robin; Camidge, D. Ross; Crino, Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1881-1888</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  The clin. benefits of crizotinib in patients with brain metastases have not been previously studied.  Patients and Methods Patients with advanced ALK-rearranged NSCLC enrolled onto clin. trial PROFILE 1005 or 1007 (randomly assigned to crizotinib) were included in this retrospective anal.  Patients with asymptomatic brain metastases (nontarget or target lesions) were allowed to enroll.  Tumor assessments were evaluated every 6 wk using RECIST (version 1.1).  Results At baseline, 31% of patients (275 of 888) had asymptomatic brain metastases; 109 had received no prior and 166 had received prior brain radiotherapy as treatment.  Among patients with previously untreated asymptomatic brain metastases, the systemic disease control rate (DCR) at 12 wk was 63% (95% CI, 54% to 72%), the intracranial DCR was 56% (95% CI, 46% to 66%), and the median intracranial time to progression (TTP) was 7 mo (95% CI, 6.7 to 16.4).  Among patients with previously treated brain metastases, the systemic DCR was 65% (95% CI, 57% to 72%), the intracranial DCR was 62% (95% CI, 54% to 70%), and the median intracranial TTP was 13.2 mo (95% CI, 9.9 to not reached).  Patients with systemic disease control were also likely to experience intracranial disease control at 12 wk (correlation coeff., 0.7652; P <.001).  Among patients without baseline brain metastases who developed progressive disease (n = 253) after initiation of crizotinib, 20% were diagnosed with brain metastases.  Conclusion Crizotinib was assocd. with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases.  However, progression of preexisting or development of new intracranial lesions while receiving therapy was a common manifestation of acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokOoSZRSEa-bVg90H21EOLACvtfcHk0lhKqQDsL1oXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM&md5=a398b73ebd0163c33c7805ffb17aabab</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.0539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.0539%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DShreeve%26aufirst%3DM.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DWiltshire%26aufirst%3DR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DCrino%26aufirst%3DL.%26atitle%3DClinical%2520Experience%2520With%2520crizotinib%2520in%2520Patients%2520With%2520Advanced%2520ALK-Rearranged%2520Non-Small-Cell%2520Lung%2520Cancer%2520and%2520Brain%2520Metastases%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D17%26spage%3D1881%26epage%3DU41%26doi%3D10.1200%2FJCO.2014.59.0539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutateladze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Mechanisms of Resistance to crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1472</span><span class="NLM_x">–</span> <span class="NLM_lpage">1482</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&issue=5&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+Resistance+to+crizotinib+in+Patients+with+ALK+Gene+Rearranged+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-11-2906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0lhKqQDsL1oXdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520crizotinib%2520in%2520Patients%2520with%2520ALK%2520Gene%2520Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D5%26spage%3D1472%26epage%3D1482%26doi%3D10.1158%2F1078-0432.CCR-11-2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varghese, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabraji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4273</span><span class="NLM_x">–</span> <span class="NLM_lpage">4281</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F1078-0432.CCR-13-0318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=23729361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4273-4281&issue=15&author=J.+F.+Gainorauthor=A.+M.+Vargheseauthor=S.+H.+I.+Ouauthor=S.+Kabrajiauthor=M.+M.+Awadauthor=R.+Katayamaauthor=A.+Pawlakauthor=M.+Mino-Kenudsonauthor=B.+Y.+Yeapauthor=G.+J.+Rielyauthor=A.+J.+Iafrateauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=J.+A.+Engelmanauthor=D.+Dias-Santagataauthor=A.+T.+Shaw&title=ALK+Rearrangements+Are+Mutually+Exclusive+with+Mutations+in+EGFR+or+KRAS%3A+An+Analysis+of+1%2C683+Patients+with+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-13-0318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Varghese, Anna M.; Ou, Sai-Hong Ignatius; Kabraji, Sheheryar; Awad, Mark M.; Katayama, Ryohei; Pawlak, Amanda; Mino-Kenudson, Mari; Yeap, Beow Y.; Riely, Gregory J.; Iafrate, A. John; Arcila, Maria E.; Ladanyi, Marc; Engelman, Jeffrey A.; Dias-Santagata, Dora; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4273-4281</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small cell lung cancer (NSCLC).  Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naive and crizotinib-resistant cancers.  Exptl. Design: We reviewed clin. genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant EGFR or KRAS mutations among patients with ALK-pos. NSCLC.  We also examd. biopsy specimens from 34 patients with ALK-pos. NSCLC after the development of resistance to crizotinib.  Results: Screening identified 301 (17.8%) EGFR mutations, 465 (27.6%) KRAS mutations, and 75 (4.4%) ALK rearrangements.  EGFR mutations and ALK rearrangements were mutually exclusive.  Four patients with KRAS mutations were found to have abnormal ALK FISH patterns, most commonly involving isolated 5' green probes.  Sufficient tissue was available for confirmatory ALK immunohistochem. in 3 cases, all of which were neg. for ALK expression.  Among patients with ALK-pos. NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were ALK FISH pos. in 29 of 29 (100%) cases.  Secondary mutations in the ALK kinase domain and ALK gene amplification were obsd. in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, resp.  No EGFR or KRAS mutations were identified among any of the 25 crizotinib-resistant, ALK-pos. patients with sufficient tissue for testing.  Conclusions: Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population.  This lack of overlap was also obsd. in ALK-pos. cancers with acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuDecyNaYQrVg90H21EOLACvtfcHk0liOoIMXEwyQ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI&md5=6355f3f634ef5b7ba06a497d0bf71a1a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0318%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DKabraji%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DPawlak%26aufirst%3DA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520Rearrangements%2520Are%2520Mutually%2520Exclusive%2520with%2520Mutations%2520in%2520EGFR%2520or%2520KRAS%253A%2520An%2520Analysis%2520of%25201%252C683%2520Patients%2520with%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D15%26spage%3D4273%26epage%3D4281%26doi%3D10.1158%2F1078-0432.CCR-13-0318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of Acquired crizotinib Resistance in ALK-Rearranged Lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">120</span><span class="NLM_x">) </span> <span class="NLM_fpage">120ra17</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&issue=120&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+Acquired+crizotinib+Resistance+in+ALK-Rearranged+Lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520crizotinib%2520Resistance%2520in%2520ALK-Rearranged%2520Lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D120%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">1734</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span><span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&issue=18&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+Mutations+in+Lung+Cancer+That+Confer+Resistance+to+ALK+Inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0liOoIMXEwyQ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Mutations%2520in%2520Lung%2520Cancer%2520That%2520Confer%2520Resistance%2520to%2520ALK%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D18%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">120</span><span class="NLM_x">) </span> <span class="NLM_fpage">120ps2</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1126%2Fscitranslmed.3003728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=22323827" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ps2&issue=120&author=C.+M.+Lovlyauthor=W.+Pao&title=Escaping+ALK+Inhibition%3A+Mechanisms+of+and+Strategies+to+Overcome+Resistance&doi=10.1126%2Fscitranslmed.3003728"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003728%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEscaping%2520ALK%2520Inhibition%253A%2520Mechanisms%2520of%2520and%2520Strategies%2520to%2520Overcome%2520Resistance%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D120%26spage%3D120ps2%26doi%3D10.1126%2Fscitranslmed.3003728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koivunen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforow, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumpfova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weremowicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6051</span><span class="NLM_x">–</span> <span class="NLM_lpage">6060</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F0008-5472.CAN-11-1340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&issue=18&author=T.+Sasakiauthor=J.+Koivunenauthor=A.+Oginoauthor=M.+Yanagitaauthor=S.+Nikiforowauthor=W.+Zhengauthor=C.+Lathanauthor=J.+P.+Marcouxauthor=J.+Y.+Duauthor=K.+Okudaauthor=M.+Capellettiauthor=T.+Shimamuraauthor=D.+Ercanauthor=M.+Stumpfovaauthor=Y.+Xiaoauthor=S.+Weremowiczauthor=M.+Butaneyauthor=S.+Heonauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=M.+J.+Eckauthor=K.+K.+Wongauthor=N.+Lindemanauthor=N.+S.+Grayauthor=S.+J.+Rodigauthor=P.+A.+Janne&title=A+Novel+ALK+Secondary+Mutation+and+EGFR+Signaling+Cause+Resistance+to+ALK+Kinase+Inhibitors&doi=10.1158%2F0008-5472.CAN-11-1340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1340%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKoivunen%26aufirst%3DJ.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DYanagita%26aufirst%3DM.%26aulast%3DNikiforow%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DLathan%26aufirst%3DC.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DDu%26aufirst%3DJ.%2BY.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DStumpfova%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DWeremowicz%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DHeon%26aufirst%3DS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DA%2520Novel%2520ALK%2520Secondary%2520Mutation%2520and%2520EGFR%2520Signaling%2520Cause%2520Resistance%2520to%2520ALK%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26issue%3D18%26spage%3D6051%26epage%3D6060%26doi%3D10.1158%2F0008-5472.CAN-11-1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">10038</span><span class="NLM_x">–</span> <span class="NLM_lpage">10043</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F0008-5472.CAN-10-2956" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10038-10043&issue=24&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+P.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+Janne&title=The+Neuroblastoma-Associated+F1174L+ALK+Mutation+Causes+Resistance+to+an+ALK+Kinase+Inhibitor+in+ALK-Translocated+Cancers&doi=10.1158%2F0008-5472.CAN-10-2956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2956%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DThe%2520Neuroblastoma-Associated%2520F1174L%2520ALK%2520Mutation%2520Causes%2520Resistance%2520to%2520an%2520ALK%2520Kinase%2520Inhibitor%2520in%2520ALK-Translocated%2520Cancers%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3D24%26spage%3D10038%26epage%3D10043%26doi%3D10.1158%2F0008-5472.CAN-10-2956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">3987</span><span class="NLM_x">–</span> <span class="NLM_lpage">3996</span><span class="refDoi"> DOI: 10.1200/JCO.2012.45.2029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1200%2FJCO.2012.45.2029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=24101047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3987-3996&issue=31&author=J.+F.+Gainorauthor=A.+T.+Shaw&title=Emerging+Paradigms+in+the+Development+of+Resistance+to+Tyrosine+Kinase+Inhibitors+in+Lung+Cancer&doi=10.1200%2FJCO.2012.45.2029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer</span></div><div class="casAuthors">Gainor, Justin F.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3987-3996</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The success of tyrosine kinase inhibitors (TKIs) in select patients with non-small-cell lung cancer (NSCLC) has transformed management of the disease, placing new emphasis on understanding the mol. characteristics of tumor specimens.  It is now recognized that genetic alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subtypes of NSCLC that are highly responsive to genotype-directed TKIs.  Despite this initial sensitivity, however, the long-term effectiveness of such therapies is universally limited by the development of resistance.  Identifying the mechanisms underlying this resistance is an area of intense, ongoing investigation.  In this review, we provide an overview of recent experience in the field, focusing on results from preclin. resistance models and studies of patient-derived, TKI-resistant tumor specimens.  Although diverse TKI resistance mechanisms have been identified within EGFR-mutant and ALK-pos. patients, we highlight common principles of resistance shared between these groups.  These include the development of secondary mutations in the kinase target, gene amplification of the primary oncogene, and upregulation of bypass signaling tracts.  In EGFR-mutant and ALK-pos. patients alike, acquired resistance may also be a dynamic and multifactorial process that may necessitate the use of treatment combinations.  We believe that insights into the mechanisms of TKI resistance in patients with EGFR mutations or ALK rearrangements may inform the development of novel treatment strategies in NSCLC, which may also be generalizable to other kinase-driven malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocpGWNEWOmKLVg90H21EOLACvtfcHk0liN7UlUihCpsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtrfE&md5=2022a0d77adc2caf5f317d629635f5d7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.45.2029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.45.2029%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DEmerging%2520Paradigms%2520in%2520the%2520Development%2520of%2520Resistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D31%26spage%3D3987%26epage%3D3996%26doi%3D10.1200%2FJCO.2012.45.2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kain, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klempner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on crizotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&issue=4&author=S.+H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-Generation+Sequencing+Reveals+a+Novel+NSCLC+ALK+F1174V+Mutation+and+Confirms+ALK+G1202R+Mutation+Confers+High-Level+Resistance+to+alectinib+%28CH5424802%2FRO5424802%29+in+ALK-Rearranged+NSCLC+Patients+Who+Progressed+on+crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-Generation%2520Sequencing%2520Reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520Mutation%2520and%2520Confirms%2520ALK%2520G1202R%2520Mutation%2520Confers%2520High-Level%2520Resistance%2520to%2520alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-Rearranged%2520NSCLC%2520Patients%2520Who%2520Progressed%2520on%2520crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">953</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span><span class="refDoi"> DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&issue=7&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0li-xPRS33MKHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26issue%3D7%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H-8,4-(metheno)pyrazolo 4,3-h 2,5,11 -benzoxadiazacyclotetradecine-3-c arbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Y.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+H.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+C.+Zhuauthor=J.+J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-+2H-8%2C4-%28metheno%29pyrazolo+4%2C3-h+2%2C5%2C11+-benzoxadiazacyclotetradecine-3-c+arbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%2BY.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%2BH.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-%25202H-8%252C4-%2528metheno%2529pyrazolo%25204%252C3-h%25202%252C5%252C11%2520-benzoxadiazacyclotetradecine-3-c%2520arbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&issue=5&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+Selective+ALK+Inhibitor+Capable+of+Blocking+the+Resistant+Gatekeeper+Mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0li4pPNa-kINdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520Selective%2520ALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520the%2520Resistant%2520Gatekeeper%2520Mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26issue%3D5%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&issue=1&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0li4pPNa-kINdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26issue%3D1%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ercheng Wang, Huiyong Sun, Junmei Wang, Zhe Wang, Hui Liu, John Z. H. Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (16)
                                     , 9478-9508. <a href="https://doi.org/10.1021/acs.chemrev.9b00055" title="DOI URL">https://doi.org/10.1021/acs.chemrev.9b00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.9b00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.9b00055%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DEnd-Point%252BBinding%252BFree%252BEnergy%252BCalculation%252Bwith%252BMM%25252FPBSA%252Band%252BMM%25252FGBSA%25253A%252BStrategies%252Band%252BApplications%252Bin%252BDrug%252BDesign%26aulast%3DWang%26aufirst%3DErcheng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21012019%26date%3D24062019%26volume%3D119%26issue%3D16%26spage%3D9478%26epage%3D9508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Jung Hee  Park</span>, <span class="hlFld-ContribAuthor ">Hoi-Yun  Jung</span>, <span class="hlFld-ContribAuthor ">Kukcheol  Ahn</span>, <span class="hlFld-ContribAuthor ">Soyeon  Choi</span>, <span class="hlFld-ContribAuthor ">Hyun Seop  Tae</span>, <span class="hlFld-ContribAuthor ">Kyung Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Jin Kyung  Rho</span>, <span class="hlFld-ContribAuthor ">Jae Cheol  Lee</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (22)
                                     , 9205-9221. <a href="https://doi.org/10.1021/acs.jmedchem.7b01039" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B4-Phenoxyquinoline%252BBased%252BInhibitors%252Bfor%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bby%252BStructure-Based%252BDesign%26aulast%3DMah%26aufirst%3DShinmee%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17072017%26date%3D09112017%26date%3D22112017%26date%3D01112017%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saemina  Shin</span>, <span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>, and <span class="hlFld-ContribAuthor ">Hwangseo  Park</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (4)
                                     , 802-810. <a href="https://doi.org/10.1021/acs.jcim.6b00026" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BLow%252BMicromolar%252BDual%252BInhibitors%252Bfor%252BWild%252BType%252Band%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bthrough%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DShin%26aufirst%3DSaemina%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20012016%26date%3D04042016%26date%3D25042016%26date%3D25032016%26volume%3D56%26issue%3D4%26spage%3D802%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Halah S.  Almutairi</span>, <span class="hlFld-ContribAuthor ">Mona M.  AlShehri</span>, <span class="hlFld-ContribAuthor ">Mohammed M.  Alanazi</span>, <span class="hlFld-ContribAuthor ">Ibrahim A.  Darwish</span>, <span class="hlFld-ContribAuthor ">Hany W.  Darwish</span>. </span><span class="cited-content_cbyCitation_article-title">Novel spectrofluorimetric determination of brigatinib in bulk powder and human urine samples via ion-pair complex formation using eosin Y. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2021,</strong> <em>249 </em>, 119210. <a href="https://doi.org/10.1016/j.saa.2020.119210" title="DOI URL">https://doi.org/10.1016/j.saa.2020.119210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2020.119210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2020.119210%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DNovel%252Bspectrofluorimetric%252Bdetermination%252Bof%252Bbrigatinib%252Bin%252Bbulk%252Bpowder%252Band%252Bhuman%252Burine%252Bsamples%252Bvia%252Bion-pair%252Bcomplex%252Bformation%252Busing%252Beosin%252BY%26aulast%3DAlmutairi%26aufirst%3DHalah%2BS.%26date%3D2021%26volume%3D249%26spage%3D119210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sitanshu S.  Singh</span>, <span class="hlFld-ContribAuthor ">Achyut  Dahal</span>, <span class="hlFld-ContribAuthor ">Leeza  Shrestha</span>, <span class="hlFld-ContribAuthor ">Seetharama D.  Jois</span>. </span><span class="cited-content_cbyCitation_article-title">Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (32)
                                     , 5274-5316. <a href="https://doi.org/10.2174/0929867326666190222183219" title="DOI URL">https://doi.org/10.2174/0929867326666190222183219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190222183219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190222183219%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DGenotype%252BDriven%252BTherapy%252Bfor%252BNon-Small%252BCell%252BLung%252BCancer%25253A%252BResistance%25252C%252BPan%252BInhibitors%252Band%252BImmunotherapy%26aulast%3DSingh%26aufirst%3DSitanshu%2BS.%26date%3D2020%26volume%3D27%26issue%3D32%26spage%3D5274%26epage%3D5316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Sicong  Liu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Yin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103456. <a href="https://doi.org/10.1016/j.bioorg.2019.103456" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-arylaminopyrimidine%252Bderivatives%252Bbearing%252B1%25252C3%25252C8-triazaspiro%25255B4%25252C5%25255Ddecan-4-one%252Bor%252Bpiperidine-3-carboxamide%252Bmoiety%252Bas%252Bnovel%252BType-I1%25252F2%252BALK%252Binhibitors%26aulast%3DMiao%26aufirst%3DXiuqi%26date%3D2020%26volume%3D94%26spage%3D103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Chung  Chuang</span>, <span class="hlFld-ContribAuthor ">Bo-Yen  Huang</span>, <span class="hlFld-ContribAuthor ">Hsin-Wen  Chang</span>, <span class="hlFld-ContribAuthor ">Chia-Ning  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-46825-1" title="DOI URL">https://doi.org/10.1038/s41598-019-46825-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-46825-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-46825-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DMolecular%252BModeling%252Bof%252BALK%252BL1198F%252Band%25252For%252BG1202R%252BMutations%252Bto%252BDetermine%252BDifferential%252BCrizotinib%252BSensitivity%26aulast%3DChuang%26aufirst%3DYu-Chung%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongrui  Lei</span>, <span class="hlFld-ContribAuthor ">Fang  Jia</span>, <span class="hlFld-ContribAuthor ">Meng  Cao</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Minglin  Zhu</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (20)
                                     , 115051. <a href="https://doi.org/10.1016/j.bmc.2019.115051" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115051%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bexploration%252Bof%252Bsolvent-front%252Bregion%252Bhigh%252Baffinity%252Bmoiety%252Bleading%252Bto%252Bnovel%252Bpotent%252BALK%252B%252526%252BROS1%252Bdual%252Binhibitors%252Bwith%252Bmutant-combating%252Beffects%26aulast%3DLei%26aufirst%3DHongrui%26date%3D2019%26volume%3D27%26issue%3D20%26spage%3D115051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magda  Bahcall</span>, <span class="hlFld-ContribAuthor ">Mark M.  Awad</span>, <span class="hlFld-ContribAuthor ">Lynette M.  Sholl</span>, <span class="hlFld-ContribAuthor ">Frederick H.  Wilson</span>, <span class="hlFld-ContribAuthor ">Man  Xu</span>, <span class="hlFld-ContribAuthor ">Stephen  Wang</span>, <span class="hlFld-ContribAuthor ">Sangeetha  Palakurthi</span>, <span class="hlFld-ContribAuthor ">Jihyun  Choi</span>, <span class="hlFld-ContribAuthor ">Elena V.  Ivanova</span>, <span class="hlFld-ContribAuthor ">Giulia C.  Leonardi</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Ulrich</span>, <span class="hlFld-ContribAuthor ">Cloud P.  Paweletz</span>, <span class="hlFld-ContribAuthor ">Paul T.  Kirschmeier</span>, <span class="hlFld-ContribAuthor ">Masayuki  Watanabe</span>, <span class="hlFld-ContribAuthor ">Hideo  Baba</span>, <span class="hlFld-ContribAuthor ">Mizuki  Nishino</span>, <span class="hlFld-ContribAuthor ">Rebecca J.  Nagy</span>, <span class="hlFld-ContribAuthor ">Richard B.  Lanman</span>, <span class="hlFld-ContribAuthor ">Marzia  Capelletti</span>, <span class="hlFld-ContribAuthor ">Emily S.  Chambers</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Redig</span>, <span class="hlFld-ContribAuthor ">Paul A.  VanderLaan</span>, <span class="hlFld-ContribAuthor ">Daniel B.  Costa</span>, <span class="hlFld-ContribAuthor ">Yu  Imamura</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>. </span><span class="cited-content_cbyCitation_article-title">Amplification of Wild-type
              KRAS
              Imparts Resistance to Crizotinib in
              MET
              Exon 14 Mutant Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (23)
                                     , 5963-5976. <a href="https://doi.org/10.1158/1078-0432.CCR-18-0876" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-18-0876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-18-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-18-0876%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DAmplification%252Bof%252BWild-type%252BKRAS%252BImparts%252BResistance%252Bto%252BCrizotinib%252Bin%252BMET%252BExon%252B14%252BMutant%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DBahcall%26aufirst%3DMagda%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D23%26spage%3D5963%26epage%3D5976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Gou</span>, <span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 322-333. <a href="https://doi.org/10.1016/j.ejmech.2018.09.012" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.012%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bpotent%252BALK%252Band%252BROS1%252Binhibitors%252Bcombating%252Bdrug-resistant%252Bmutants%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Baminopyridine-containing%252Bdiarylaminopyrimidine%252Bderivatives%26aulast%3DGuo%26aufirst%3DMing%26date%3D2018%26volume%3D158%26spage%3D322%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silky  Bedi</span>, <span class="hlFld-ContribAuthor ">Shah A.  Khan</span>, <span class="hlFld-ContribAuthor ">Majed M.  AbuKhader</span>, <span class="hlFld-ContribAuthor ">Perwez  Alam</span>, <span class="hlFld-ContribAuthor ">Nasir A.  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Asif  Husain</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Saudi Pharmaceutical Journal</span><span> <strong>2018,</strong> <em>26 </em>
                                    (6)
                                     , 755-763. <a href="https://doi.org/10.1016/j.jsps.2018.04.010" title="DOI URL">https://doi.org/10.1016/j.jsps.2018.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsps.2018.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsps.2018.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Pharmaceutical%2520Journal%26atitle%3DA%252Bcomprehensive%252Breview%252Bon%252BBrigatinib%252B%2525E2%252580%252593%252BA%252Bwonder%252Bdrug%252Bfor%252Btargeted%252Bcancer%252Btherapy%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DBedi%26aufirst%3DSilky%26date%3D2018%26volume%3D26%26issue%3D6%26spage%3D755%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Guowei  Wu</span>, <span class="hlFld-ContribAuthor ">Chuyue  Zeng</span>, <span class="hlFld-ContribAuthor ">Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Fan  Meng</span>, <span class="hlFld-ContribAuthor ">Sherrina  Patel</span>, <span class="hlFld-ContribAuthor ">Wenqiu  Wang</span>, <span class="hlFld-ContribAuthor ">Scott B.  Ficarro</span>, <span class="hlFld-ContribAuthor ">Alan L.  Leggett</span>, <span class="hlFld-ContribAuthor ">Chelsea E.  Powell</span>, <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>, <span class="hlFld-ContribAuthor ">Kang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jacky Chi  Ki Ngo</span>, <span class="hlFld-ContribAuthor ">Xiang-Dong  Fu</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2018,</strong> <em>25 </em>
                                    (4)
                                     , 460-470.e6. <a href="https://doi.org/10.1016/j.chembiol.2018.01.013" title="DOI URL">https://doi.org/10.1016/j.chembiol.2018.01.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2018.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2018.01.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DSRPKIN-1%25253A%252BA%252BCovalent%252BSRPK1%25252F2%252BInhibitor%252Bthat%252BPotently%252BConverts%252BVEGF%252Bfrom%252BPro-angiogenic%252Bto%252BAnti-angiogenic%252BIsoform%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2018%26volume%3D25%26issue%3D4%26spage%3D460%26epage%3D470.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Shaowei  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Hu</span>, <span class="hlFld-ContribAuthor ">Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Gou</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Yucheng  Gu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 123-136. <a href="https://doi.org/10.1016/j.ejmech.2017.11.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Band%252BROS1%252Bdual%252Binhibitors%252Bto%252Bovercome%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DWang%26aufirst%3DYu%26date%3D2018%26volume%3D143%26spage%3D123%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaijun  Geng</span>, <span class="hlFld-ContribAuthor ">Zongjun  Xia</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Ruisi (Ruthy)  Zhang</span>, <span class="hlFld-ContribAuthor ">Deqiao  Sun</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 386-397. <a href="https://doi.org/10.1016/j.ejmech.2017.12.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4-diarylaminopyrimidines%252Bbearing%252Ba%252Bresorcinol%252Bmotif%252Bas%252Bnovel%252BALK%252Binhibitors%252Bto%252Bovercome%252Bthe%252BG1202R%252Bresistant%252Bmutation%26aulast%3DGeng%26aufirst%3DKaijun%26date%3D2018%26volume%3D144%26spage%3D386%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Zaman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Sulman  Basit</span>, <span class="hlFld-ContribAuthor ">Abdul  Ghaffar</span>, <span class="hlFld-ContribAuthor ">Muhammad Sohail  Zafar</span>, <span class="hlFld-ContribAuthor ">Aamer  Saeed</span>, <span class="hlFld-ContribAuthor ">Sultan Ayoub  Meo</span>. </span><span class="cited-content_cbyCitation_article-title">Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (30)
                                     , 16470-16493. <a href="https://doi.org/10.1039/C8RA01934G" title="DOI URL">https://doi.org/10.1039/C8RA01934G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA01934G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA01934G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DLatest%252Bperspectives%252Bof%252Borally%252Bbioavailable%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252B%252528DAAPalogues%252529%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Bdiscovery%252Band%252Bclinical%252Bdevelopments%26aulast%3DLatif%26aufirst%3DMuhammad%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D30%26spage%3D16470%26epage%3D16493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>177 </em>, 1-8. <a href="https://doi.org/10.1016/j.pharmthera.2017.02.015" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTherapeutic%252Bstrategies%252Band%252Bmechanisms%252Bof%252Bdrug%252Bresistance%252Bin%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529-rearranged%252Blung%252Bcancer%26aulast%3DKatayama%26aufirst%3DRyohei%26date%3D2017%26volume%3D177%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaebong  Jang</span>, <span class="hlFld-ContribAuthor ">Jung Beom  Son</span>, <span class="hlFld-ContribAuthor ">Ciric  To</span>, <span class="hlFld-ContribAuthor ">Magda  Bahcall</span>, <span class="hlFld-ContribAuthor ">So Young  Kim</span>, <span class="hlFld-ContribAuthor ">Seock Yong  Kang</span>, <span class="hlFld-ContribAuthor ">Mierzhati  Mushajiang</span>, <span class="hlFld-ContribAuthor ">Younho  Lee</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Hwan Geun  Choi</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a potent dual ALK and EGFR T790M inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 497-510. <a href="https://doi.org/10.1016/j.ejmech.2017.04.079" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.079%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bpotent%252Bdual%252BALK%252Band%252BEGFR%252BT790M%252Binhibitor%26aulast%3DJang%26aufirst%3DJaebong%26date%3D2017%26volume%3D136%26spage%3D497%26epage%3D510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors of ALK. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 435-467. <a href="https://doi.org/10.1007/7355_2017_18" title="DOI URL">https://doi.org/10.1007/7355_2017_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_18%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecule%252BInhibitors%252Bof%252BALK%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2017%26spage%3D435%26epage%3D467%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Tsui</span>, <span class="hlFld-ContribAuthor ">Q.  Zeng</span>, <span class="hlFld-ContribAuthor ">K.  Chen</span>, <span class="hlFld-ContribAuthor ">X.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting Kinases in the CNS. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 408-446. <a href="https://doi.org/10.1016/B978-0-12-409547-2.13815-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.13815-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.13815-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.13815-6%26sid%3Dliteratum%253Aachs%26atitle%3DInhibiting%252BKinases%252Bin%252Bthe%252BCNS%26aulast%3DTsui%26aufirst%3DH.%26date%3D2017%26spage%3D408%26epage%3D446%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Chung Hyo  Kang</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Raghavendra  Achary</span>, <span class="hlFld-ContribAuthor ">Ha-Yeon  Lee</span>, <span class="hlFld-ContribAuthor ">Joo-Youn  Lee</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Hee Jung  Jung</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 536-549. <a href="https://doi.org/10.1016/j.ejmech.2016.11.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DReplacing%252Bthe%252Bterminal%252Bpiperidine%252Bin%252Bceritinib%252Bwith%252Baliphatic%252Bamines%252Bconfers%252Bactivities%252Bagainst%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DMathi%26aufirst%3DGangadhar%2BRao%26date%3D2017%26volume%3D126%26spage%3D536%26epage%3D549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sen  Zhang</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Rachel  Squillace</span>, <span class="hlFld-ContribAuthor ">Sara  Nadworny</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Jeff  Keats</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Scott D.  Wardwell</span>, <span class="hlFld-ContribAuthor ">David  Miller</span>, <span class="hlFld-ContribAuthor ">Youngchul  Song</span>, <span class="hlFld-ContribAuthor ">Lindsey  Eichinger</span>, <span class="hlFld-ContribAuthor ">Lauren  Moran</span>, <span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Shuangying  Liu</span>, <span class="hlFld-ContribAuthor ">Dong  Zou</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Qurish  Mohemmad</span>, <span class="hlFld-ContribAuthor ">Hyun Gyung  Jang</span>, <span class="hlFld-ContribAuthor ">Emily  Ye</span>, <span class="hlFld-ContribAuthor ">Narayana  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Juan  Miret</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">David  Dalgarno</span>, <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>. </span><span class="cited-content_cbyCitation_article-title">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2016,</strong> <em>22 </em>
                                    (22)
                                     , 5527-5538. <a href="https://doi.org/10.1158/1078-0432.CCR-16-0569" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-16-0569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DThe%252BPotent%252BALK%252BInhibitor%252BBrigatinib%252B%252528AP26113%252529%252BOvercomes%252BMechanisms%252Bof%252BResistance%252Bto%252BFirst-%252Band%252BSecond-Generation%252BALK%252BInhibitors%252Bin%252BPreclinical%252BModels%26aulast%3DZhang%26aufirst%3DSen%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D22%26spage%3D5527%26epage%3D5538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chung Hyo  Kang</span>, <span class="hlFld-ContribAuthor ">Eun-Young  Kim</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Hye Gwang  Jeong</span>, <span class="hlFld-ContribAuthor ">Sang Un  Choi</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Joo-Youn  Lee</span>, <span class="hlFld-ContribAuthor ">You Hwa  Son</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Byung Hoi  Lee</span>, <span class="hlFld-ContribAuthor ">Heejung  Jung</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2016,</strong> <em>374 </em>
                                    (2)
                                     , 272-278. <a href="https://doi.org/10.1016/j.canlet.2016.02.009" title="DOI URL">https://doi.org/10.1016/j.canlet.2016.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2016.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2016.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DMinor%252Bmodifications%252Bto%252Bceritinib%252Benhance%252Banti-tumor%252Bactivity%252Bin%252BEML4-ALK%252Bpositive%252Bcancer%26aulast%3DKang%26aufirst%3DChung%2BHyo%26date%3D2016%26volume%3D374%26issue%3D2%26spage%3D272%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit Dipak  Amin</span>, <span class="hlFld-ContribAuthor ">Lingxiao  Li</span>, <span class="hlFld-ContribAuthor ">Soumya S.  Rajan</span>, <span class="hlFld-ContribAuthor ">Vijay  Gokhale</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Groysman</span>, <span class="hlFld-ContribAuthor ">Praechompoo  Pongtornpipat</span>, <span class="hlFld-ContribAuthor ">Edgar O.  Tapia</span>, <span class="hlFld-ContribAuthor ">Mengdie  Wang</span>, <span class="hlFld-ContribAuthor ">Jonathan H.  Schatz</span>. </span><span class="cited-content_cbyCitation_article-title">TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (17)
                                     , 23715-23729. <a href="https://doi.org/10.18632/oncotarget.8173" title="DOI URL">https://doi.org/10.18632/oncotarget.8173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.8173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.8173%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTKI%252Bsensitivity%252Bpatterns%252Bof%252Bnovel%252Bkinase-domain%252Bmutations%252Bsuggest%252Btherapeutic%252Bopportunities%252Bfor%252Bpatients%252Bwith%252Bresistant%252BALK%25252B%252Btumors%26aulast%3DAmin%26aufirst%3DAmit%2BDipak%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D17%26spage%3D23715%26epage%3D23729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of <b>1</b> in complex with wild-type ALK and docked pose of <b>1</b> with a molecular model of ALK<sup>G1202R</sup>. (A) Binding conformation of <b>1</b> (yellow stick) in the ATP binding site of ALK<sup>WT</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>). Hydrogen bonds are indicated by dashed lines. (B) Binding conformation of <b>1</b> in the ATP binding site of ALK with a model of the G1202R mutation. Hydrogen bonds are indicated by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Western blotting in NIH-3t3 cells transformed with wild-type EML4-ALK or its crizotinib-resistant secondary mutants. (A) Western blotting of crizotinib, ceritinib, alectinib, and compound <b>6</b> against EML4-ALK<sup>WT</sup> NIH-3T3 and EML4-ALK<sup>G1202R</sup> NIH-3T3. (B) Western blotting of crizotinib, ceritinib, alectinib, and compound <b>6</b> against crizotinib-resistant mutants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Molecular docking study of <b>6</b> with wild-type ALK and a model of G1202R ALK. (A) Binding conformation of <b>6</b> (yellow sticks) in the ATP binding site of ALK<sup>WT</sup> (blue ribbon). Hydrogen bonds are indicated by dashed lines. (B) Predicted binding conformation of <b>6</b> (yellow sticks) in the ATP binding site of ALK<sup>G1202R</sup>. Hydrogen bonds are indicated by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ambit kinomescan selectivity results for compounds <b>6</b> and <b>32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Pyrazole Analogue <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 6 mol % Pd(dppf)Cl<sub>2</sub>, 8 mol % <i>t</i>-BuXphos, 5 equiv of 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 1 h, then 2 equiv of LiOH, H<sub>2</sub>O, rt; (b) 1.2 equiv of dimethylamine hydrochloride, 2 equiv of HATU, 5 equiv of DIEA, DMF, 54%.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Alkyl Heterocycle Analogue <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 6 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 9 mol % tris(<i>o</i>-tolyl)phosphine, 8 equiv of NaO-<i>t</i>-Bu, 1,4-dioxane, 110 °C, 2 h, 48%.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Triazole Analogue <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 5 mol % Pd(OAc)<sub>2</sub>, 12 mol % PPh<sub>3</sub>, 11 mol % CuI, Et<sub>2</sub>NH, 90 °C, 4 h, then 3 equiv of TBAF, THF, 4 h; (b) 1.5 equiv of TMS-N<sub>3</sub>, 5 mol % CuI, DMF, MeOH, 100 °C, 4 h, 36%.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/medium/jm-2015-01136d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diol and Carboxylic Acid Analogues <b>22</b> and <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01136&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 6 mol % Pd(dppf)Cl<sub>2</sub>, 8 mol % <i>t</i>-BuXphos, 5 equiv of 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 1 h; (b) 5 mol % AD-mix β, <i>t</i>-BuOH, H<sub>2</sub>O, 0 °C to rt, 12 h, 51%; (c) 1 mol % OSO<sub>4</sub>, 4 equiv of Oxone, rt, 6 h, 82%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. P.</span><span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">2175</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span><span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&issue=18&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+L.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%2BL.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26issue%3D18%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bilsland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mead, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Znamenskiy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz-Sanjuan, I.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/sj.npp.1301446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fsj.npp.1301446" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=685-700&issue=3&author=J.+G.+Bilslandauthor=A.+Wheeldonauthor=A.+Meadauthor=P.+Znamenskiyauthor=S.+Almondauthor=K.+A.+Watersauthor=M.+Thakurauthor=V.+Beaumontauthor=T.+P.+Bonnertauthor=R.+Heavensauthor=P.+Whitingauthor=G.+McAllisterauthor=I.+Munoz-Sanjuan&title=Behavioral+and+neurochemical+alterations+in+mice+deficient+in+anaplastic+lymphoma+kinase+suggest+therapeutic+potential+for+psychiatric+indications&doi=10.1038%2Fsj.npp.1301446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301446%26sid%3Dliteratum%253Aachs%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DZnamenskiy%26aufirst%3DP.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DThakur%26aufirst%3DM.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DBonnert%26aufirst%3DT.%2BP.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DBehavioral%2520and%2520neurochemical%2520alterations%2520in%2520mice%2520deficient%2520in%2520anaplastic%2520lymphoma%2520kinase%2520suggest%2520therapeutic%2520potential%2520for%2520psychiatric%2520indications%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26issue%3D3%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fsj.npp.1301446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1056/NEJMoa1006448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&issue=18&author=E.+L.+Kwakauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=B.+Solomonauthor=R.+G.+Makiauthor=S.+H.+I.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+Janneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.+H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+Lymphoma+Kinase+Inhibition+in+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1006448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0li5mSMqxj6bPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520Inhibition%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D18%26spage%3D1693%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1006448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Lebeau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doane, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardiman, J. W.</span><span> </span><span class="NLM_article-title">The T(2–5)(P23-Q35) - A Recurring Chromosomal Abnormality in KI-1-Positive Anaplastic Large Cell Lymphoma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">870</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1989&pages=866-870&issue=12&author=M.+M.+Lebeauauthor=M.+A.+Bitterauthor=R.+A.+Larsonauthor=L.+A.+Doaneauthor=E.+D.+Ellisauthor=W.+A.+Franklinauthor=C.+M.+Rubinauthor=M.+E.+Kadinauthor=J.+W.+Vardiman&title=The+T%282%E2%80%935%29%28P23-Q35%29+-+A+Recurring+Chromosomal+Abnormality+in+KI-1-Positive+Anaplastic+Large+Cell+Lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLebeau%26aufirst%3DM.%2BM.%26aulast%3DBitter%26aufirst%3DM.%2BA.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DDoane%26aufirst%3DL.%2BA.%26aulast%3DEllis%26aufirst%3DE.%2BD.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DRubin%26aufirst%3DC.%2BM.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520T%25282%25E2%2580%25935%2529%2528P23-Q35%2529%2520-%2520A%2520Recurring%2520Chromosomal%2520Abnormality%2520in%2520KI-1-Positive%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%26jtitle%3DLeukemia%26date%3D1989%26volume%3D3%26issue%3D12%26spage%3D866%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&issue=12&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26issue%3D12%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehner, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, D. A.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor - A comparative immunohistochemical study</span> <span class="citation_source-journal">Am. J. Surg. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1364</span><span class="NLM_x">–</span> <span class="NLM_lpage">1371</span><span class="refDoi"> DOI: 10.1097/00000478-200111000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1097%2F00000478-200111000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=11684952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A280%3ADC%252BD3MnkvVehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=1364-1371&issue=11&author=J.+R.+Cookauthor=L.+P.+Dehnerauthor=M.+H.+Collinsauthor=Z.+G.+Maauthor=S.+W.+Morrisauthor=C.+M.+Coffinauthor=D.+A.+Hill&title=Anaplastic+lymphoma+kinase+%28ALK%29+expression+in+the+inflammatory+myofibroblastic+tumor+-+A+comparative+immunohistochemical+study&doi=10.1097%2F00000478-200111000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study</span></div><div class="casAuthors">Cook J R; Dehner L P; Collins M H; Ma Z; Morris S W; Coffin C M; Hill D A</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1364-71</span>
        ISSN:<span class="NLM_cas:issn">0147-5185</span>.
    </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is an uncommon mesenchymal neoplasm with a variable histologic appearance that may mimic other spindle cell processes, particularly nodular fasciitis, desmoid tumor, and in intra-abdominal locations, gastrointestinal stromal tumor.  Recently, gene fusions involving ALK at chromosome 2p23 have been described in IMTs.  The resultant ALK protein overexpression in the myofibroblastic component of these tumors is detectable by immunohistochemistry.  We examined 73 IMTs, 20 cases of nodular fasciitis, 15 desmoid fibromatoses, and 15 gastrointestinal stromal tumors by immunohistochemistry using ALK-11, a rabbit polyclonal antibody that recognizes the C-terminus of the protein.  ALK positivity was detected in 44 of 73 (60%) IMTs.  All cases of nodular fasciitis, desmoid fibromatosis, and gastrointestinal stromal tumors were ALK negative (p < 0.001).  These findings demonstrate that ALK positivity is common in IMTs, and immunohistochemistry using anti-ALK antibodies can be helpful in the differential diagnosis of these neoplasms.  In addition, anti-ALK staining seems to correlate with those IMTs that have the typical tri-patterned histologic appearance and clinical presentation, providing additional support to the premise that IMT is a distinctive clinicopathologic entity within the broad category of inflammatory pseudotumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8OlyInGEWUlw2ofyr07jXfW6udTcc2eaGox9fbQzEQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnkvVehtw%253D%253D&md5=6875da498f3a364ebac2a2d8971798dd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2F00000478-200111000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000478-200111000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DDehner%26aufirst%3DL.%2BP.%26aulast%3DCollins%26aufirst%3DM.%2BH.%26aulast%3DMa%26aufirst%3DZ.%2BG.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DCoffin%26aufirst%3DC.%2BM.%26aulast%3DHill%26aufirst%3DD.%2BA.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520expression%2520in%2520the%2520inflammatory%2520myofibroblastic%2520tumor%2520-%2520A%2520comparative%2520immunohistochemical%2520study%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2001%26volume%3D25%26issue%3D11%26spage%3D1364%26epage%3D1371%26doi%3D10.1097%2F00000478-200111000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Subero, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestou, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auvigne, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delsol, G.</span><span> </span><span class="NLM_article-title">ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2568</span><span class="NLM_x">–</span> <span class="NLM_lpage">2573</span><span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&issue=7&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+Muller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+diffuse+large+B-cell+lymphoma+is+associated+with+Clathrin-ALK+rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520diffuse%2520large%2520B-cell%2520lymphoma%2520is%2520associated%2520with%2520Clathrin-ALK%2520rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26issue%3D7%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Jazii, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najafi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malekzadeh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrads, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziaee, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abnet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazdznbod, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karkhane, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salekdeh, G. H.</span><span> </span><span class="NLM_article-title">Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">44</span><span class="NLM_x">) </span> <span class="NLM_fpage">7104</span><span class="NLM_x">–</span> <span class="NLM_lpage">7112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.3748%2Fwjg.v12.i44.7104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=17131471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=7104-7112&issue=44&author=F.+R.+Jaziiauthor=Z.+Najafiauthor=R.+Malekzadehauthor=T.+P.+Conradsauthor=A.+A.+Ziaeeauthor=C.+Abnetauthor=M.+Yazdznbodauthor=A.+A.+Karkhaneauthor=G.+H.+Salekdeh&title=Identification+of+squamous+cell+carcinoma+associated+proteins+by+proteomics+and+loss+of+beta+tropomyosin+expression+in+esophageal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer</span></div><div class="casAuthors">Jazii, Ferdous Rastgar; Najafi, Zahra; Malekzadeh, Reza; Conrads, Thomas P.; Ziaee, Abed Ali; Abnet, Christian; Yazdznbod, Mansour; Karkhane, Ali Asghar; Salekdeh, Ghasem H.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">7104-7112</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">To assess the proteome of normal vs. tumor tissue in squamous cell carcinoma of the esophagus (SCCE) in Iranian patients and compare our results with former reports by using proteomics.  Protein was extd. from normal and tumor tissues.  Two dimensional electrophoresis was carried out and spots with differential expression were identified with mass spectrometry.  RNA extn. and RT-PCR along with immunodetection were performed.  Fourteen proteins were found whose expression levels differed in tumor compared to normal tissues.  Mass spectrometric anal. resulted in the identification of β-tropomyosin (TMβ), myosin light chain 2 (and its isoform), myosin regulatory light chain 2, peroxyredoxin 2, annexin I and an unknown polypeptide as the down regulated polypeptides in tumor tissue.  Heat shock protein 70 (HSP70), TPM4-ALK fusion oncoprotein 2, myosin light polypeptide 6, keratin I, GH16431p and calreticulin were the up-regulated polypeptides found in tumor tissue.  Several of these proteins, such as TMβ, HSP70, annexin I, calreticulin, TPM4-ALK and isoforms of myosins, have been well recognized in tumorigenesis of esophageal or other types of cancers.  The study not only supports the involvement of some of the formerly reported proteins in SCCE but also introduces addnl. proteins found to be lost in SCCE, including TMβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQBiL27ZRH7Vg90H21EOLACvtfcHk0lhWrEybPtb7Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D&md5=2de4e4dc1639b4414afa8ea6e072c22c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v12.i44.7104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v12.i44.7104%26sid%3Dliteratum%253Aachs%26aulast%3DJazii%26aufirst%3DF.%2BR.%26aulast%3DNajafi%26aufirst%3DZ.%26aulast%3DMalekzadeh%26aufirst%3DR.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DZiaee%26aufirst%3DA.%2BA.%26aulast%3DAbnet%26aufirst%3DC.%26aulast%3DYazdznbod%26aufirst%3DM.%26aulast%3DKarkhane%26aufirst%3DA.%2BA.%26aulast%3DSalekdeh%26aufirst%3DG.%2BH.%26atitle%3DIdentification%2520of%2520squamous%2520cell%2520carcinoma%2520associated%2520proteins%2520by%2520proteomics%2520and%2520loss%2520of%2520beta%2520tropomyosin%2520expression%2520in%2520esophageal%2520cancer%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2006%26volume%3D12%26issue%3D44%26spage%3D7104%26epage%3D7112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x"> (</span><span class="NLM_issue">7153</span><span class="NLM_x">) </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">U3</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-U3&issue=7153&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+I.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lhWrEybPtb7Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%2BI.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26issue%3D7153%26spage%3D561%26epage%3DU3%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x"> (</span><span class="NLM_issue">7215</span><span class="NLM_x">) </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">U51</span><span class="refDoi"> DOI: 10.1038/nature07398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-U51&issue=7215&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma&doi=10.1038%2Fnature07398"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26issue%3D7215%26spage%3D967%26epage%3DU51%26doi%3D10.1038%2Fnature07398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provide a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x"> (</span><span class="NLM_issue">7215</span><span class="NLM_x">) </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1038/nature07397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnature07397" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&issue=7215&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+M.+Zhangauthor=Y.+Ahnauthor=W.+J.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Q.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provide+a+therapeutic+target+in+neuroblastoma&doi=10.1038%2Fnature07397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature07397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07397%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%2BM.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%2BQ.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provide%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26issue%3D7215%26spage%3D975%26epage%3D978%26doi%3D10.1038%2Fnature07397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The ALK Inhibitor ceritinib Overcomes crizotinib Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">673</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&issue=6&author=L.+Fribouletauthor=N.+X.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.+Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Y.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+Inhibitor+ceritinib+Overcomes+crizotinib+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0liePCqu0-aHlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%2BX.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%2BY.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520Inhibitor%2520ceritinib%2520Overcomes%2520crizotinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D6%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekhail, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tursi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span> </span><span class="NLM_article-title">First-Line crizotinib versus Chemotherapy in ALK-Positive Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2177</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1408440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25470694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2167-2177&issue=23&author=B.+J.+Solomonauthor=T.+Mokauthor=D.+W.+Kimauthor=Y.+L.+Wuauthor=K.+Nakagawaauthor=T.+Mekhailauthor=E.+Felipauthor=F.+Cappuzzoauthor=J.+Paoliniauthor=T.+Usariauthor=S.+Iyerauthor=A.+Reismanauthor=K.+D.+Wilnerauthor=J.+Tursiauthor=F.+Blackhall&title=First-Line+crizotinib+versus+Chemotherapy+in+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1408440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span></div><div class="casAuthors">Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2167-2177/1-2167-2177/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with std. chemotherapy as first-line treatment for advanced ALK-pos. non-small-cell lung cancer (NSCLC) is unknown.  METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-pos. nonsquamous NSCLC who had received no previous systemic treatment for advanced disease.  Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive i.v. chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per mL per min) every 3 wk for up to six cycles.  Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy.  The primary end point was progression-free survival as assessed by independent radiol. review.  RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 mo vs. 7.0 mo; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).  Objective response rates were 74% and 45 %, resp. (P<0.001).  Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-yr survival was 84% with crizotinib and 79% with chemotherapy.  The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.  As compared with chemotherapy, crizotinib was assocd. with greater redn. in lung cancer symptoms and greater improvement in quality of life.  CONCLUSIONS Crizotinib was superior to std. first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7N7XM7ywBLVg90H21EOLACvtfcHk0librjVUAwpnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D&md5=afd3c75ef95aff5c0fa12b6b7e22b46a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408440%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPaolini%26aufirst%3DJ.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DReisman%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DTursi%26aufirst%3DJ.%26aulast%3DBlackhall%26aufirst%3DF.%26atitle%3DFirst-Line%2520crizotinib%2520versus%2520Chemotherapy%2520in%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D23%26spage%3D2167%26epage%3D2177%26doi%3D10.1056%2FNEJMoa1408440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Byrne, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro-Sibilot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tassell, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2394</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&issue=25&author=A.+T.+Shawauthor=D.+W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crinoauthor=M.+J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.+L.+Wuauthor=M.+Thomasauthor=K.+J.+O%27Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+Janne&title=crizotinib+versus+Chemotherapy+in+Advanced+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0librjVUAwpnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%2527Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3Dcrizotinib%2520versus%2520Chemotherapy%2520in%2520Advanced%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26issue%3D25%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25322323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=429-439&issue=7&author=M.+M.+Awadauthor=A.+T.+Shaw&title=ALK+Inhibitors+in+Non-Small+Cell+Lung+Cancer%3A+Crizotinib+and+Beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: crizotinib and beyond</span></div><div class="casAuthors">Awad Mark M; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">429-39</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.  Resistance to crizotinib invariably develops, however, through a variety of mechanisms.  In the last few years, a flurry of new and more potent ALK inhibitors has emerged for the treatment of ALK-positive NSCLC, including ceritinib (LDK378), alectinib (RO5424802/CH5424802), AP26113, ASP3026, TSR-011, PF-06463922, RXDX-101, X-396, and CEP-37440.  Cancers harboring ALK rearrangements may also be susceptible to treatment with heat shock protein 90 inhibitors.  This review focuses on the pharmacologic and clinical properties of these compounds, either as monotherapies or in combination with other drugs.  With so many ALK inhibitors in development, the challenges of how these agents should be studied and ultimately prescribed are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTc4MrEK-FRv9pSBfyDvp7fW6udTcc2eai-XjZYPtnlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D&md5=ae4655774258c9265a283749559ac393</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520Inhibitors%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Crizotinib%2520and%2520Beyond%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D12%26issue%3D7%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltshire, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span> </span><span class="NLM_article-title">Clinical Experience With crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">1881</span><span class="NLM_x">–</span> <span class="NLM_lpage">U41</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.0539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1200%2FJCO.2014.59.0539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25624436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1881-U41&issue=17&author=D.+B.+Costaauthor=A.+T.+Shawauthor=S.+H.+I.+Ouauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=M.+J.+Ahnauthor=C.+C.+Zhouauthor=M.+Shreeveauthor=P.+Selaruauthor=A.+Polliauthor=P.+Schnellauthor=K.+D.+Wilnerauthor=R.+Wiltshireauthor=D.+R.+Camidgeauthor=L.+Crino&title=Clinical+Experience+With+crizotinib+in+Patients+With+Advanced+ALK-Rearranged+Non-Small-Cell+Lung+Cancer+and+Brain+Metastases&doi=10.1200%2FJCO.2014.59.0539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</span></div><div class="casAuthors">Costa, Daniel B.; Shaw, Alice T.; Ou, Sai-Hong I.; Solomon, Benjamin J.; Riely, Gregory J.; Ahn, Myung-Ju; Zhou, Caicun; Shreeve, S. Martin; Selaru, Paulina; Polli, Anna; Schnell, Patrick; Wilner, Keith D.; Wiltshire, Robin; Camidge, D. Ross; Crino, Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1881-1888</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  The clin. benefits of crizotinib in patients with brain metastases have not been previously studied.  Patients and Methods Patients with advanced ALK-rearranged NSCLC enrolled onto clin. trial PROFILE 1005 or 1007 (randomly assigned to crizotinib) were included in this retrospective anal.  Patients with asymptomatic brain metastases (nontarget or target lesions) were allowed to enroll.  Tumor assessments were evaluated every 6 wk using RECIST (version 1.1).  Results At baseline, 31% of patients (275 of 888) had asymptomatic brain metastases; 109 had received no prior and 166 had received prior brain radiotherapy as treatment.  Among patients with previously untreated asymptomatic brain metastases, the systemic disease control rate (DCR) at 12 wk was 63% (95% CI, 54% to 72%), the intracranial DCR was 56% (95% CI, 46% to 66%), and the median intracranial time to progression (TTP) was 7 mo (95% CI, 6.7 to 16.4).  Among patients with previously treated brain metastases, the systemic DCR was 65% (95% CI, 57% to 72%), the intracranial DCR was 62% (95% CI, 54% to 70%), and the median intracranial TTP was 13.2 mo (95% CI, 9.9 to not reached).  Patients with systemic disease control were also likely to experience intracranial disease control at 12 wk (correlation coeff., 0.7652; P <.001).  Among patients without baseline brain metastases who developed progressive disease (n = 253) after initiation of crizotinib, 20% were diagnosed with brain metastases.  Conclusion Crizotinib was assocd. with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases.  However, progression of preexisting or development of new intracranial lesions while receiving therapy was a common manifestation of acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokOoSZRSEa-bVg90H21EOLACvtfcHk0ljC_BSJUWR1NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM&md5=a398b73ebd0163c33c7805ffb17aabab</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.0539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.0539%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DShreeve%26aufirst%3DM.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DWiltshire%26aufirst%3DR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DCrino%26aufirst%3DL.%26atitle%3DClinical%2520Experience%2520With%2520crizotinib%2520in%2520Patients%2520With%2520Advanced%2520ALK-Rearranged%2520Non-Small-Cell%2520Lung%2520Cancer%2520and%2520Brain%2520Metastases%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D17%26spage%3D1881%26epage%3DU41%26doi%3D10.1200%2FJCO.2014.59.0539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutateladze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Mechanisms of Resistance to crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1472</span><span class="NLM_x">–</span> <span class="NLM_lpage">1482</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&issue=5&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+Resistance+to+crizotinib+in+Patients+with+ALK+Gene+Rearranged+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-11-2906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0ljC_BSJUWR1NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520crizotinib%2520in%2520Patients%2520with%2520ALK%2520Gene%2520Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D5%26spage%3D1472%26epage%3D1482%26doi%3D10.1158%2F1078-0432.CCR-11-2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varghese, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabraji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4273</span><span class="NLM_x">–</span> <span class="NLM_lpage">4281</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F1078-0432.CCR-13-0318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=23729361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4273-4281&issue=15&author=J.+F.+Gainorauthor=A.+M.+Vargheseauthor=S.+H.+I.+Ouauthor=S.+Kabrajiauthor=M.+M.+Awadauthor=R.+Katayamaauthor=A.+Pawlakauthor=M.+Mino-Kenudsonauthor=B.+Y.+Yeapauthor=G.+J.+Rielyauthor=A.+J.+Iafrateauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=J.+A.+Engelmanauthor=D.+Dias-Santagataauthor=A.+T.+Shaw&title=ALK+Rearrangements+Are+Mutually+Exclusive+with+Mutations+in+EGFR+or+KRAS%3A+An+Analysis+of+1%2C683+Patients+with+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-13-0318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Varghese, Anna M.; Ou, Sai-Hong Ignatius; Kabraji, Sheheryar; Awad, Mark M.; Katayama, Ryohei; Pawlak, Amanda; Mino-Kenudson, Mari; Yeap, Beow Y.; Riely, Gregory J.; Iafrate, A. John; Arcila, Maria E.; Ladanyi, Marc; Engelman, Jeffrey A.; Dias-Santagata, Dora; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4273-4281</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small cell lung cancer (NSCLC).  Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naive and crizotinib-resistant cancers.  Exptl. Design: We reviewed clin. genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant EGFR or KRAS mutations among patients with ALK-pos. NSCLC.  We also examd. biopsy specimens from 34 patients with ALK-pos. NSCLC after the development of resistance to crizotinib.  Results: Screening identified 301 (17.8%) EGFR mutations, 465 (27.6%) KRAS mutations, and 75 (4.4%) ALK rearrangements.  EGFR mutations and ALK rearrangements were mutually exclusive.  Four patients with KRAS mutations were found to have abnormal ALK FISH patterns, most commonly involving isolated 5' green probes.  Sufficient tissue was available for confirmatory ALK immunohistochem. in 3 cases, all of which were neg. for ALK expression.  Among patients with ALK-pos. NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were ALK FISH pos. in 29 of 29 (100%) cases.  Secondary mutations in the ALK kinase domain and ALK gene amplification were obsd. in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, resp.  No EGFR or KRAS mutations were identified among any of the 25 crizotinib-resistant, ALK-pos. patients with sufficient tissue for testing.  Conclusions: Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population.  This lack of overlap was also obsd. in ALK-pos. cancers with acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuDecyNaYQrVg90H21EOLACvtfcHk0ljC_BSJUWR1NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI&md5=6355f3f634ef5b7ba06a497d0bf71a1a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0318%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DKabraji%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DPawlak%26aufirst%3DA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520Rearrangements%2520Are%2520Mutually%2520Exclusive%2520with%2520Mutations%2520in%2520EGFR%2520or%2520KRAS%253A%2520An%2520Analysis%2520of%25201%252C683%2520Patients%2520with%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D15%26spage%3D4273%26epage%3D4281%26doi%3D10.1158%2F1078-0432.CCR-13-0318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of Acquired crizotinib Resistance in ALK-Rearranged Lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">120</span><span class="NLM_x">) </span> <span class="NLM_fpage">120ra17</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&issue=120&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+Acquired+crizotinib+Resistance+in+ALK-Rearranged+Lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520crizotinib%2520Resistance%2520in%2520ALK-Rearranged%2520Lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D120%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">1734</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span><span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&issue=18&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+Mutations+in+Lung+Cancer+That+Confer+Resistance+to+ALK+Inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0liiJIK_9Ak3hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Mutations%2520in%2520Lung%2520Cancer%2520That%2520Confer%2520Resistance%2520to%2520ALK%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D18%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">120</span><span class="NLM_x">) </span> <span class="NLM_fpage">120ps2</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1126%2Fscitranslmed.3003728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=22323827" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ps2&issue=120&author=C.+M.+Lovlyauthor=W.+Pao&title=Escaping+ALK+Inhibition%3A+Mechanisms+of+and+Strategies+to+Overcome+Resistance&doi=10.1126%2Fscitranslmed.3003728"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003728%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEscaping%2520ALK%2520Inhibition%253A%2520Mechanisms%2520of%2520and%2520Strategies%2520to%2520Overcome%2520Resistance%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D120%26spage%3D120ps2%26doi%3D10.1126%2Fscitranslmed.3003728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koivunen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforow, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumpfova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weremowicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6051</span><span class="NLM_x">–</span> <span class="NLM_lpage">6060</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F0008-5472.CAN-11-1340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&issue=18&author=T.+Sasakiauthor=J.+Koivunenauthor=A.+Oginoauthor=M.+Yanagitaauthor=S.+Nikiforowauthor=W.+Zhengauthor=C.+Lathanauthor=J.+P.+Marcouxauthor=J.+Y.+Duauthor=K.+Okudaauthor=M.+Capellettiauthor=T.+Shimamuraauthor=D.+Ercanauthor=M.+Stumpfovaauthor=Y.+Xiaoauthor=S.+Weremowiczauthor=M.+Butaneyauthor=S.+Heonauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=M.+J.+Eckauthor=K.+K.+Wongauthor=N.+Lindemanauthor=N.+S.+Grayauthor=S.+J.+Rodigauthor=P.+A.+Janne&title=A+Novel+ALK+Secondary+Mutation+and+EGFR+Signaling+Cause+Resistance+to+ALK+Kinase+Inhibitors&doi=10.1158%2F0008-5472.CAN-11-1340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1340%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKoivunen%26aufirst%3DJ.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DYanagita%26aufirst%3DM.%26aulast%3DNikiforow%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DLathan%26aufirst%3DC.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DDu%26aufirst%3DJ.%2BY.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DStumpfova%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DWeremowicz%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DHeon%26aufirst%3DS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DA%2520Novel%2520ALK%2520Secondary%2520Mutation%2520and%2520EGFR%2520Signaling%2520Cause%2520Resistance%2520to%2520ALK%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26issue%3D18%26spage%3D6051%26epage%3D6060%26doi%3D10.1158%2F0008-5472.CAN-11-1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">10038</span><span class="NLM_x">–</span> <span class="NLM_lpage">10043</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1158%2F0008-5472.CAN-10-2956" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10038-10043&issue=24&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+P.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+Janne&title=The+Neuroblastoma-Associated+F1174L+ALK+Mutation+Causes+Resistance+to+an+ALK+Kinase+Inhibitor+in+ALK-Translocated+Cancers&doi=10.1158%2F0008-5472.CAN-10-2956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2956%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DThe%2520Neuroblastoma-Associated%2520F1174L%2520ALK%2520Mutation%2520Causes%2520Resistance%2520to%2520an%2520ALK%2520Kinase%2520Inhibitor%2520in%2520ALK-Translocated%2520Cancers%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3D24%26spage%3D10038%26epage%3D10043%26doi%3D10.1158%2F0008-5472.CAN-10-2956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">3987</span><span class="NLM_x">–</span> <span class="NLM_lpage">3996</span><span class="refDoi"> DOI: 10.1200/JCO.2012.45.2029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1200%2FJCO.2012.45.2029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=24101047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3987-3996&issue=31&author=J.+F.+Gainorauthor=A.+T.+Shaw&title=Emerging+Paradigms+in+the+Development+of+Resistance+to+Tyrosine+Kinase+Inhibitors+in+Lung+Cancer&doi=10.1200%2FJCO.2012.45.2029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer</span></div><div class="casAuthors">Gainor, Justin F.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3987-3996</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The success of tyrosine kinase inhibitors (TKIs) in select patients with non-small-cell lung cancer (NSCLC) has transformed management of the disease, placing new emphasis on understanding the mol. characteristics of tumor specimens.  It is now recognized that genetic alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subtypes of NSCLC that are highly responsive to genotype-directed TKIs.  Despite this initial sensitivity, however, the long-term effectiveness of such therapies is universally limited by the development of resistance.  Identifying the mechanisms underlying this resistance is an area of intense, ongoing investigation.  In this review, we provide an overview of recent experience in the field, focusing on results from preclin. resistance models and studies of patient-derived, TKI-resistant tumor specimens.  Although diverse TKI resistance mechanisms have been identified within EGFR-mutant and ALK-pos. patients, we highlight common principles of resistance shared between these groups.  These include the development of secondary mutations in the kinase target, gene amplification of the primary oncogene, and upregulation of bypass signaling tracts.  In EGFR-mutant and ALK-pos. patients alike, acquired resistance may also be a dynamic and multifactorial process that may necessitate the use of treatment combinations.  We believe that insights into the mechanisms of TKI resistance in patients with EGFR mutations or ALK rearrangements may inform the development of novel treatment strategies in NSCLC, which may also be generalizable to other kinase-driven malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocpGWNEWOmKLVg90H21EOLACvtfcHk0lj6PXaN58ls3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtrfE&md5=2022a0d77adc2caf5f317d629635f5d7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.45.2029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.45.2029%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DEmerging%2520Paradigms%2520in%2520the%2520Development%2520of%2520Resistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D31%26spage%3D3987%26epage%3D3996%26doi%3D10.1200%2FJCO.2012.45.2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kain, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klempner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on crizotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&issue=4&author=S.+H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-Generation+Sequencing+Reveals+a+Novel+NSCLC+ALK+F1174V+Mutation+and+Confirms+ALK+G1202R+Mutation+Confers+High-Level+Resistance+to+alectinib+%28CH5424802%2FRO5424802%29+in+ALK-Rearranged+NSCLC+Patients+Who+Progressed+on+crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-Generation%2520Sequencing%2520Reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520Mutation%2520and%2520Confirms%2520ALK%2520G1202R%2520Mutation%2520Confers%2520High-Level%2520Resistance%2520to%2520alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-Rearranged%2520NSCLC%2520Patients%2520Who%2520Progressed%2520on%2520crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">953</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span><span class="refDoi"> DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&issue=7&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0lj6PXaN58ls3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26issue%3D7%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H-8,4-(metheno)pyrazolo 4,3-h 2,5,11 -benzoxadiazacyclotetradecine-3-c arbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Y.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+H.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+C.+Zhuauthor=J.+J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-+2H-8%2C4-%28metheno%29pyrazolo+4%2C3-h+2%2C5%2C11+-benzoxadiazacyclotetradecine-3-c+arbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%2BY.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%2BH.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-%25202H-8%252C4-%2528metheno%2529pyrazolo%25204%252C3-h%25202%252C5%252C11%2520-benzoxadiazacyclotetradecine-3-c%2520arbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&issue=5&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+Selective+ALK+Inhibitor+Capable+of+Blocking+the+Resistant+Gatekeeper+Mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhbqysWlOeKxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520Selective%2520ALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520the%2520Resistant%2520Gatekeeper%2520Mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26issue%3D5%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&issue=1&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhHmtYzbNIM0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26issue%3D1%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX','PDB','3AOX'); return false;">PDB: 3AOX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01136">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_57884"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01136">10.1021/acs.jmedchem.5b01136</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Ba/F3 cellular IC<sub>50</sub> curves for crizotinib, ceritinib, alectinib, and compound <b>6</b>, cellular IC<sub>50</sub> curves for patient-derived NSCLC cells and neuroblastoma cells for compound <b>6</b>, cellular IC<sub>50</sub> values with standard deviations for crizotinib, ceritinib, alectinib, and compound <b>6</b>, and full Ambit profiling for compounds <b>6</b> and <b>32</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Simplified molecular-input line-entry system (SMILES) data for compounds <b>6</b>–<b>36</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_001.pdf">jm5b01136_si_001.pdf (1.46 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01136/suppl_file/jm5b01136_si_002.csv">jm5b01136_si_002.csv (3.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01136%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01136" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f50fc9edd1b3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
